0001104659-21-071224.txt : 20210524 0001104659-21-071224.hdr.sgml : 20210524 20210524163045 ACCESSION NUMBER: 0001104659-21-071224 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210524 DATE AS OF CHANGE: 20210524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biostage, Inc. CENTRAL INDEX KEY: 0001563665 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 455210462 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35853 FILM NUMBER: 21955391 BUSINESS ADDRESS: STREET 1: 84 OCTOBER HILL ROAD STREET 2: SUITE 11 CITY: HOLLISTON STATE: MA ZIP: 01746 BUSINESS PHONE: (774) 233-7300 MAIL ADDRESS: STREET 1: 84 OCTOBER HILL ROAD STREET 2: SUITE 11 CITY: HOLLISTON STATE: MA ZIP: 01746 FORMER COMPANY: FORMER CONFORMED NAME: Harvard Apparatus Regenerative Technology, Inc. DATE OF NAME CHANGE: 20121204 10-Q 1 tm2111640d1_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2021

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission file number 001-35853

BIOSTAGE, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

45-5210462

(State or Other Jurisdiction of

Incorporation or Organization)

(IRS Employer

Identification No.)

84 October Hill Road, Suite 11, Holliston, MA		01746
(Address of Principal Executive Offices)		(Zip Code)

(774) 233-7300

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x YES ¨ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x YES ¨ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨

Non-accelerated filer x	Smaller reporting company x

	Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ¨ YES x NO

As of May 21, 2021, there were 9,388,407 shares of common stock, par value $0.01 per share, outstanding.

Biostage Inc.

Form 10-Q

For the Quarter Ended March 31, 2021

INDEX

		Page
PART I-FINANCIAL INFORMATION		3

Item 1.	Consolidated Financial Statements (unaudited)	3

	Consolidated Balance Sheets	3

	Consolidated Statements of Operations	4

	Consolidated Statements of Stockholders’ Equity	5

	Consolidated Statements of Cash Flows	6

	Notes to Unaudited Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4.	Controls and Procedures	19

PART II-OTHER INFORMATION		20

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 6	Exhibits	21

SIGNATURES		22

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements.

BIOSTAGE, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share data)

	March 31, 2021			December 31, 2020
	(Unaudited)
ASSETS
Current assets:
Cash	$	466		$	1,026
Restricted cash		50			50
Grant receivable		22			77
Prepaid expenses and other current assets		388			524
Total current assets		926			1,677
Property, plant and equipment, net		174			217
Right-of-use assets		156			182
Total assets	$	1,256		$	2,076

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	81		$	31
Accrued and other current liabilities		220			317
Current portion of notes payable		346			284
Warrant liability		14			17
Current portion of operating lease liability		110			107
Total current liabilities		771			756
Notes payable, net of current portion		58			120
Operating lease liability, net of current portion		46			75
Total liabilities	$	875		$	951

Commitments and contingencies (Note 7)

Stockholders’ equity:
Preferred stock, $0.01 par value; 2,000,000 shares authorized as of March 31, 2021 and December 31, 2020, 0 issued and outstanding	$	-		$	-
Common stock, par value $0.01 per share, 60,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 9,388,407 issued and outstanding at March 31, 2021 and December 31, 2020		94			94
Additional paid-in capital		70,121			69,991
Accumulated deficit		(69,834	)		(68,960	)
Total stockholders’ equity		381			1,125
Total liabilities and stockholders’ equity	$	1,256		$	2,076

See accompanying notes to unaudited consolidated financial statements.

BIOSTAGE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share amounts)

	Three Months Ended March 31,
	2021			2020
Revenues	$	-		$	-

Operating expenses:
Research and development		473			643
Selling, general and administrative		522			1,253
Total operating expenses		995			1,896

Operating loss		(995	)		(1,896	)

Other income (expense):
Grant income		118			-
Change in fair value of warrant liability		3			(100	)
Total other income (expense), net		121			(100	)

Net loss	$	(874	)	$	(1,996	)

Basic and diluted net loss per share	$	(0.09	)	$	(0.24	)
Weighted-average common shares, basic and diluted		9,388			8,287

See accompanying notes to unaudited consolidated financial statements.

BIOSTAGE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)

(In thousands)

	Three Months Ended March 31, 2021
	Number of Common Shares Outstanding		Common Stock		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2020		9,388	$	94	$	69,991	$	(68,960	)	$	1,125

Net loss		-		-		-		(874	)		(874	)
Share-based compensation		-		-		130		-			130
Balance at March 31, 2021		9,388	$	94	$	70,121	$	(69,834	)	$	381

	Three Months Ended March 31, 2020
	Number of Common Shares Outstanding		Common Stock		Additional Paid-in Capital			Accumulated Deficit			Total Stockholders' Equity
Balance at December 31, 2019		8,156	$	82	$	65,102		$	(64,095	)	$	1,089

Net loss		-		-		-			(1,996	)		(1,996	)
Share-based compensation		-		-		588			-			588
Issuance of fully vested common shares		12		-		(24	)		-			(24	)
Issuance of common stock and warrants to purchase common stock		151		1		558			-			559
Issuance of common stock from exercise of warrants		214		2		426			-			428
Balance at March 31, 2020		8,533	$	85	$	66,650		$	(66,091	)	$	644

See accompanying notes to unaudited consolidated financial statements.

BIOSTAGE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Three Months Ended March 31,
	2021			2020
OPERATING ACTIVITIES
Net loss	$	(874	)	$	(1,996	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense		130			588
Depreciation		43			48
Change in fair value of warrant liability		(3	)		100
Changes in operating assets and liabilities:
Grant receivable		55			-
Prepaid expenses and other current assets		136			98
Accounts payable		50			(14	)
Accrued and other current liabilities		(97	)		82
Net cash used in operating activities		(560	)		(1,094	)

INVESTING ACTIVITIES
Net cash used in investing activities	$	-		$	-

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants		-			559
Proceeds from exercise of warrants		-			428
Net cash provided by financing activities		-			987
Net decrease in cash and restricted cash		(560	)		(107	)
Cash and restricted cash at beginning of period		1,076			963
Cash and restricted cash at end of period	$	516		$	856

See accompanying notes to unaudited consolidated financial statements.

BIOSTAGE, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

1.	Overview and Basis of Presentation

Overview

Biostage, Inc. (Biostage or the Company) is a biotechnology company developing bioengineered organ implants based on the Company’s novel Cellframe ™ and Cellspan ™ technology. The Company’s technology is comprised of a proprietary biocompatible scaffold, which is the foundation of the Company’s Cellframe technology, that is seeded with the recipient’s own mesenchymal stromal cells to form the Company’s Cellspan implant. The Company believes that this technology may provide surgeons a new paradigm to address life-threatening conditions of the esophagus, bronchus, and trachea due to congenital abnormalities, diseases, infections and traumas. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. The Company has one business segment and does not have significant costs or assets outside the United States.

On October 31, 2013, Harvard Bioscience, Inc. (Harvard Bioscience) contributed its regenerative medicine business assets, plus $15 million of cash, into Biostage (formerly “Harvard Apparatus Regenerative Technologies” at time of spin-off.) On November 1, 2013, the spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of all the shares of common stock of Biostage to stockholders of Harvard Bioscience (the “Distribution”).

The Company’s common stock is currently traded on the OTCQB Venture Market under the symbol “BSTG”.

Going Concern

The Company has incurred substantial operating losses since its inception, and as of March 31, 2021 has an accumulated deficit of approximately $69.8 million and will require additional financing to fund future operations.

The Company expects that its operating cash on-hand as of March 31, 2021 of $0.5 million, along with cash proceeds of approximately $0.3 million received in May of 2021 from existing investors, will enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2021. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

The Company will need to raise additional funds to fund its operations. In the event the Company does not raise additional capital from outside sources in the second quarter, it may be forced to curtail or cease its operations. Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of products, as well as regulatory efforts and collaborative arrangements necessary for the Company’s products that are currently under development. The Company is currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorable terms, if at all.

The Company’s operations will be adversely affected if it is unable to raise or obtain needed funding and such circumstance may materially affect the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.

Basis of Presentation

The consolidated financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (GAAP).

Use of Estimates

The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, expenses and related disclosures. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of expenses. Actual results may differ from these estimates.

Net Loss Per Share

Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including the assumed exercise of stock options, warrants, and the impact of unvested restricted stock.

The Company applies the two-class method to calculate basic and diluted net loss per share attributable to common stockholders as its warrants to purchase common stock are participating securities.

The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. However, the two-class method does not impact the net loss per share of common stock as the Company has been in a net loss position and the warrant holders do not participate in losses.

Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred.

Unaudited Interim Financial Information

The accompanying interim consolidated balance sheet as of March 31, 2021, consolidated interim statements of operations and stockholders’ equity for the three months ended March 31, 2021 and 2020, and consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2021, its consolidated results of operations, consolidated statement of cash flows, and consolidated stockholders’ equity for the three-month periods ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three-month periods ended March 31, 2021 and 2020 are unaudited. The results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period.

2.	Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies

The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K.

SBIR Award

Grant income is recognized when qualified research and development costs are incurred and recorded in other income (expense), net in the consolidated statements of operations. When evaluating grant revenue from the SBIR grant, the Company considered accounting requirements under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts With Customers. The Company concluded that ASC 606 did not apply as there is no exchange of goods or services or an exchange of intellectual property between the parties; therefore, the Company presents grant income in other income.

On March 28, 2018, the Company was awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testing of pediatric Cellspan™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 million of qualified research and development costs which was received and recognized as grant income during 2018.

On October 26, 2018, the Company was awarded the Phase II Fast-Track SBIR grant from the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinic through September 2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, the Company was awarded a third year of the Phase II grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualified expenses incurred from October 1, 2019 through September 30, 2020. In September of 2020, the Company filed and was granted a one year, no-cost extension for the Phase II grant period extending through September 30, 2021.

For the three months ended March 31, 2021, the Company recognized $0.1 million of grant income, from Phase II of the SBIR grant. The aggregate SBIR grant to date provides a total award of $1.8 million, of which, approximately $1.4 million has been recognized through March 31, 2021.

The Company did not recognize any grant income during the three months ended March 31, 2020.

Restricted Cash

Restricted cash consists of $50,000 held as collateral for the Company’s credit card program as of March 31, 2021 and December 31, 2020. The Company’s statements of cash flows include restricted cash with cash when reconciling the beginning-of-period and end-of-period total amounts shown on such statements.

A reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statements of cash flows is as follows:

	March 31,		December 31,
	2021		2020

	(In thousands)
Cash	$	466	$	806
Restricted cash		50		50
Total cash and restricted cash as shown in the statements of cash flows	$	516	$	856

Recently Adopted Accounting Pronouncements

Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption.

3.	Notes Payable

On May 4, 2020, the Company obtained a loan (Loan) from the Bank of America (Lender) in the aggregate amount of $0.4 million, pursuant to the Paycheck Protection Plan (PPP), established as part of the CARES Act. The Loan is evidenced by a promissory note dated May 4, 2020 issued by the Company and will accrue interest at a fixed interest rate of 1% per annum from the funding date of May 4, 2020. Payments of principal and interest have been deferred since the funding under the original terms of the promissory note. However, the Loan and accrued interest may be forgivable at the conclusion of this period.

Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The terms of the promissory note, including eligibility and forgiveness, may be subject to additional requirements adopted by the SBA. Any unforgiven portion of the PPP loan, including principal and interest, will mature on May 4, 2022 and will be required to be payable monthly. The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

The Company has accounted for the loan under FASB ASC 470, Debt. Repayment amounts due within one year have been recorded as current liabilities, and the remaining amounts due in more than one year as long-term liabilities. On December 18, 2020, the Company submitted the loan forgiveness application for the entire borrowings of $0.4 million to the Lender and was notified on January 7, 2021 that the application was submitted to the Small Business Administration (SBA) for review. The SBA had up to 90 days from the date of submittal to make a final decision on loan forgiveness. The Company has yet to be notified of the SBA’s forgiveness decision.

If the Company is successful in receiving forgiveness for any portion of the loan used for qualifying expenses, those amounts will be recorded as a gain upon extinguishment.

4.	Capital Stock

During the three months ended March 31, 2020, the Company issued a total of 151,027 shares of our common stock at a purchase price of $3.70 per share and warrants to purchase 151,027 shares of common stock at an exercise price of $3.70 per share to a group of investors for aggregate gross and net proceeds of approximately $0.6 million, of which, $0.5 million and $0.1 million was allocated to the common stock and warrants, respectively. The Company has classified these warrants on its consolidated balance sheets as equity and valued using the Black-Scholes model based on the following weighted average assumptions:

Risk-free interest rate		0.88	%
Expected volatility		106.7	%
Expected term		2 months
Expected dividend yield		-
Exercise price	$	3.70
Market value of common stock	$	3.11

During the three months ended March 31, 2020, the Company also issued 214,000 shares of our common stock to a group of investors in connection with the exercise of 214,000 previously issued warrants at $2.00 per share for aggregate gross and net proceeds of approximately $0.4 million.

During the three months ended March 31, 2020, the Company issued a total of 11,950 shares of our common stock to employees due to the vesting of restricted stock units and issuance of a common stock award.

5.	Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The Company utilizes a valuation hierarchy for disclosure of the inputs to the valuations used to measure fair value that prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

The Company had no assets or liabilities classified as Level 2 as of March 31, 2021 and December 31, 2020. The Company’s restricted cash that serves as collateral for the Company’s credit card program is held in a demand money market account and is measured at fair value based on quoted prices, which are Level 1 inputs. The Company classifies warrants to purchase common stock that are accounted for as liabilities as Level 3 liabilities, as discussed below.

The following table presents a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2021:

	Warrant Liability
	(In thousands)
Balance at December 31, 2020	$	17
Change in fair value upon re-measurement		(3	)
Balance at March 31, 2021	$	14

The Company has re-measured the warrant liability to estimated fair value at inception, prior to modification and at each reporting date using the Black-Scholes option pricing model with the following weighted average assumptions:

	March 31, 2021			December 31, 2020
Risk-free interest rate		0.16	%		0.12	%
Expected volatility		140.08	%		137.89	%
Expected term (in years)		0.9			1.1
Expected dividend yield		-			-
Exercise price	$	8.00		$	8.00
Market value of common stock	$	1.34		$	1.25
Warrants to purchase shares of common stock		92,212			92,212

6.	Share-Based Compensation

Biostage Amended and Restated Equity Incentive Plan

The Company maintains the Amended and Restated Equity Incentive Plan (the Plan) for the benefit of certain officers, employees, non-employee directors, and other key persons (including consultants and advisory board members). All options and awards granted under the Plan consist of the Company’s shares of common stock. The Company’s policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and the vesting of restricted stock units. The vesting period for awards is generally four years and the contractual life is ten years. Canceled and forfeited options and awards are available to be reissued under the Plan.

In June 2020, the Company’s shareholders approved the Plan to, among other things, increase of the number of shares of the Company’s common stock available for issuance pursuant thereto by 3,000,000 shares, which increased the total shares authorized to be issued under the Plan to 5,098,000. There were 3,461,091 shares available for issuance as of March 31, 2021.

The Company has granted options to purchase common stock under the Plan. Stock option activity during the three months ended March 31, 2021 was as follows:

	Stock Options
	Amount		Weighted– average exercise price
Outstanding at December 31, 2020		1,599,720	$	6.33
Granted		16,413		1.80
Canceled		-		-
Outstanding at March 31, 2021		1,616,134	$	6.31

The Company’s outstanding stock options include 338,663 performance-based awards that have vesting provisions subject to the achievement of certain business milestones. Total unrecognized compensation expense for the remaining 243,532 performance-based awards is approximately $0.8 million. No expense has been recognized for these unvested awards as of March 31, 2021 given that the milestone achievements for these awards have not yet been deemed probable for accounting purposes.

Aggregate intrinsic value for outstanding options and exercisable options for the year ended March 31, 2021 was $0 based on the Company’s closing stock price of $1.34 per share as of March 31, 2021. As of March 31, 2021, unrecognized compensation cost related to unvested nonperformance-based awards amounted to $0.3 million, which will be recognized over a weighted average period of 0.3 years.

The Company uses the Black-Scholes option pricing model to value its stock options. The weighted average assumptions for valuing options granted during the three months ended March 31, 2021 were as follows:

Risk-free interest rate	0.47	%
Expected volatility	123.20	%
Expected term	5.3 years
Expected dividend yield	n/a

In February 2020, as part of the termination arrangement with the Company’s former chief executive officer, the Company modified certain options to purchase 236,970 shares of common stock, issued an 80,000 fully vested stock option grant, and accelerated the vesting of 3,300 restricted stock units resulting in recording $153,000, $70,000, and $4,000, respectively, of share-based compensation during the three months ended March 31, 2020.

In March 2020, the Company issued 35,000 common stock awards to an employee that was earned upon the achievement of certain milestones. One of the milestones for 15,000 common shares was achieved on March 27, 2020, and the Company issued 9,795 fully vested share of common stock to the employee with 5,205 common shares withheld to cover taxes. During the three months ended March 31, 2020, the Company recognized a total of $74,800 of share-based compensation with the remaining expense of $65,200 recognized upon the achievement of certain milestones over the requisite service period during the three months ended June 30, 2020.

The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations:

	Three Months Ended March 31,
	2021		2020

	(In thousands)
Research and development	$	80	$	92
General and administrative		50		496
Total share-based compensation	$	130	$	588

The Company estimates the fair value of non-employee share options using the Black-Scholes option pricing model reflecting the same assumptions as applied to employee and director options in each of the reporting periods, other than the expected life, which is assumed to be the remaining contractual life of the options.

7.	Commitments and Contingencies

On April 14, 2017, representatives for the estate of a deceased individual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company and Harvard Bioscience. The complaint alleges that the decedent’s injury and death were caused by two tracheal implants that incorporated synthetic trachea scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in two surgeries performed in 2012 and 2013. The civil complaint seeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuit relates to the Company’s first-generation trachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Cellspan technology nor to its lead development product candidate, the Cellspan Esophageal Implant. The Company intends to vigorously defend this case. While the Company believes that such claim lacks merit, the Company is unable to predict the ultimate outcome of such litigation. In accordance with a separation and distribution agreement between Harvard Bioscience and the Company relating to the spin-off, the Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer as a result of this litigation. The Company has been informed by its insurance provider that the case has been accepted as an insurable claim under the Company’s product liability insurance policy. The Company does not believe a loss is probable at this time and therefore has not accrued any amounts for this contingent liability.

From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. Other than the above matter, there are no such matters pending that the Company expects to be material in relation to its business, financial condition, results of operations, or cash flows.

8.	Leases

The Company leases laboratory and office space and certain equipment with remaining terms ranging approximately from 1 year to 3.5 years.

The laboratory and office space arrangement is under a sublease that was renewed in December of 2020 and currently extends through May 31, 2022. This lease automatically renews annually for a one-year period unless the Company or the counterparty provides a notice of termination within one hundred and eighty days prior to May 31 of each year.

All of the Company’s leases qualify as operating leases. The following table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets:

		For the Quarter ended March 31
(In thousands)	Balance Sheet Classification	2021		2020
Assets:
Operating lease assets	Right-of-use asset	$	156	$	166
Liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	110	$	105
Non-current operating lease liabilities	Operating lease liabilities, net of current portion	$	46	$	61
Total operating lease liabilities		$	156	$	166

Cash paid included in the computation of the right of use asset and lease liability during the three months ended March 31, 2021 and 2020 amounted to approximately $30,000, respectively.

The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:

	As of March 31,
	2021			2020
Weighted average remaining lease term (in years)		1.72			2.20
Weighted average discount rate		10.24	%		13.13	%

The Company recorded lease expense in the following expense categories of its consolidated statements of operations:

		For the Three Months Ended March 31,
(In thousands)	Statement of Operations Classification	2021		2020
Operating lease expense	Research and development	$	19	$	19
	Selling, general and administrative		11		11
		$	30	$	30

The minimum lease payments for the next five years are expected to be as follows:

(In thousands)	As Of March 31, 2021
2020	$	91
2021		62
2022		12
2023		7
2024		-
Total lease payments	$	172
Less: imputed interest		16
Present value of operating lease liabilities	$	156

9.	Net Loss Per Share

Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding.

The following potential common shares were excluded from the calculation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2021 and 2020 because including them would have had an anti-dilutive effect:

	Three Months Ended March 31,
	2021		2020
Warrants to purchase common stock		1,893,201		2,610,078
Options to purchase common stock		1,616,134		1,607,570
Common stock awards		-		20,000
Total		3,509,335		4,237,648

10.

Income Taxes

The Company did not record a federal or state income tax provision or benefit for the three months ended March 31, 2021 and 2020, respectively, due to the expected loss before income taxes to be incurred for the years ended December 31, 2021 and 2020, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets.

11.

Subsequent Events

Equity Transactions

In May 2021, the Company received aggregate gross and net proceeds of approximately $0.3 million from a group of existing investors.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

This Quarterly Report on Form 10-Q contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). The forward-looking statements are principally, but not exclusively, contained in “Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements about management’s confidence or expectations and our plans, objectives, expectations and intentions that are not historical facts and the potential impact of COVID-19 on our business and operations. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “goals,” “sees,” “estimates,” “projects,” “predicts,” “intends,” “think,” “potential,” “objectives,” “optimistic,” “strategy,” and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Factors that may cause our actual results to differ materially from those in the forward-looking statements include our ability to access debt and equity markets and raise additional funds when needed; the success of our collaborations, clinical trials and pre-clinical development efforts and programs, which success may not be achieved on a timely basis or at all; our ability to obtain and maintain regulatory approval for our implant products, bioreactors, scaffolds and other devices we pursue, including for the esophagus or airway, which approvals may not be obtained on a timely basis or at all; the number of patients who can be treated with our products; the amount and timing of costs associated with our development of implant products, bioreactors, scaffolds and other devices; our failure to comply with regulations and any changes in regulations; unpredictable difficulties or delays in the development of new technology; our collaborators or other third parties we contract with, including with respect to conducting any clinical trial or pre-clinical development efforts, not devoting sufficient time and resources to successfully carry out their duties or meet expected deadlines; our ability to attract and retain qualified personnel and key employees and retain senior management; potential liability exposure with respect to our products; the availability and price of acceptable raw materials and components from third-party suppliers; difficulties in obtaining or retaining the management and other human resource competencies that we need to achieve our business objectives; increased competition in the field of regenerative medicine and bioengineering, and the financial resources of our competitors; our ability to obtain and maintain intellectual property protection for our device and product candidates; our inability to implement our growth strategy; the control our principal stockholders can exert based on holding a majority of voting power; plus factors described under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (the “SEC”) on April 13, 2021 or described in our other public filings. Our results may also be affected by factors of which we are not currently aware. We may not update these forward-looking statements, even though our situation may change in the future, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

Biostage, Inc. is referred to herein as “we,” “our,” “us,” and “the Company”.

Business Overview

We are a biotechnology company developing bioengineered organ implants based on our novel technology. Our technology is comprised of a proprietary biocompatible scaffold, which is the foundation of our Cellframe ™ technology, that is seeded with the recipient’s own mesenchymal stromal cells to form our Cellspan ™ implant, combining the clinically proven principles of tissue engineering, cell biology and materials science. This technology is being developed to treat life-threatening conditions of the esophagus, trachea and bronchus with the objective of dramatically improving the treatment paradigm for those patients.

We believe our technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, diseases, infections and traumas. Products being developed based on our technology for those indications are called Cellspan products. We are pursuing our Cellspan Esophageal Implant (CEI) technology as our first product candidate to address both esophageal disease and pediatric esophageal atresia, and we are also developing our technology’s applications to address conditions of the bronchus and trachea.

In collaboration with world-class institutions, such as Mayo Clinic and Connecticut Children’s Medical Center, we are advancing our technology. Our product development program is based on the greatest medical unmet needs, analysis of existing surgical options and physician validation.

In October 2019, we filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to treat patients with esophageal disease, absent of cancer, in adults that would require a short segment esophageal implant following clinically indicated short segment resection of the thoracic esophagus with our CEI product candidate. In November 2019, we received notice from the FDA placing our IND on clinical hold and providing a preliminary list of clinical hold and non-clinical hold questions. In December 2019, we received the formal letter with clinical hold and non-clinical hold questions and submitted our response to the clinical hold questions on February 18, 2020. On March 19, 2020, the FDA notified us that the IND for our CEI product candidate has been removed from clinical hold and that we can proceed with our study. This FDA approval enables us to start our transition to a clinical-stage biotechnology company, and start clinical planning, engaging with a clinical research organization and site readiness in advance of starting the clinical trial for our CEI product candidate. On May 7, 2020, we submitted responses to certain non-clinical hold questions and finalized a majority of remaining non-clinical hold responses in the third quarter of 2020, and submitted the remaining responses in the fourth quarter of 2020, except for responses to our clinical trial details that we will submit once a clinical research organization is selected. The COVID-19 pandemic could adversely impact our business, including planned clinical trials, as discussed elsewhere in this document.

We believe that receiving regulatory approval to treat pediatric esophageal atresia with our CEI may provide a shorter time to a commercial product and the greater overall potential value in the U.S. market. In addition to providing a novel solution for a great medical need, approval of our pediatric esophageal atresia product candidate may result in receipt of a priority review voucher, which if achieved, could potentially provide significant value and non-dilutive funding to Biostage in the future. We have continued to advance our CEI pediatric esophagus program and plan to file a protocol amendment with the FDA to update our CEI esophageal disease clinical program after the initial adult patients are treated in the esophageal disease trial, subject to FDA approval.

We have also formed a subsidiary in Hong Kong, Harvard Apparatus Regenerative Technology Limited, as we continue to assess the market and regulatory approval pathway in China as to our implant products. We are not certain at this time as to which market, including U.S. or China for example, may provide the most viable initial pathway for regulatory approval to a commercial product. This will depend on a number of factors, including the approval and development processes, related costs, ability to raise capital and the terms and conditions thereof, as well as the ongoing impact of the COVID-19 pandemic, among other factors. Any development and capital raising efforts in China may include a joint venture in relation to our Hong Kong subsidiary, and would also involve a number of commercial variables, including rights and obligations pertaining to licensing, development and financing, among others. Our failure to receive or obtain such clearances or approvals on a timely basis or at all, whether that be in the U.S., China or otherwise, would have an adverse effect on our results of operations.

Our products are currently in development and have not yet received regulatory approval for sale anywhere in the world.

Financial Condition and Need for Additional Funds

We expect to continue to incur operating losses and negative cash flows from operations for 2021 and in future years.

Operating Losses and Cash Requirements

We have incurred substantial operating losses since our inception, and as of March 31, 2021 had an accumulated deficit of approximately $69.8 million and will require additional financing to fund future operations. We expect that our operating cash on-hand as of March 31, 2021 of approximately $0.5 million along with cash proceeds of approximately $0.3 million received in May of 2021 from existing investors, will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2021. We expect to continue to incur operating losses and negative cash flows from operations for 2021 and in future years. Therefore, as disclosed in Note 1 to our consolidated financial statements, these conditions raise substantial doubt about our ability to continue as a going concern.

We will need to raise additional funds to fund our operations. In the event we do not raise additional capital from outside sources in the second quarter, we may be forced to curtail or cease its operations. Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of products, as well as regulatory efforts and collaborative arrangements necessary for our products that are currently under development. We are currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. We may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. We may not be able to obtain additional financing on favorable terms, if at all.

Our operations will be adversely affected if it is unable to raise or obtain needed funding and may materially affect our ability to continue as a going concern. Our consolidated financial statements have been prepared assuming that we will continue as a going concern and therefore, the consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty.

Small Business Innovation Research Grant

On March 28, 2018, we were awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testing of pediatric Cellspan™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 million of qualified research and development costs which was received and recognized as grant income during 2018.

On October 26, 2018, we were awarded the Phase II Fast-Track SBIR grant from the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinic through September 2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, we were awarded a third year of the Phase II grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualified expenses incurred from October 1, 2019 through September 30, 2020. In September of 2020, we filed and were granted a one year, no-cost extension for the Phase II grant period extending through September 30, 2021.

For the three months ended March 31, 2021 and 2020, we recognized $0.1 million and $0.0 million of grant income, respectively, from Phase II of the SBIR grant. The aggregate SBIR grant to date provides a total award of $1.8 million, of which, approximately $1.4 million has been recognized through March 31, 2021.

Management

We disclosed in our Current Report on Form 8-K dated February 7, 2020 that James McGorry, our former Chief Executive Officer, resigned from his role effective February 7, 2020. We also disclosed in our Current Report on Form 8-K dated August 31, 2020 that Peter Chakoutis, our Vice President of Finance, had taken a leave of absence from his role for personal reasons effective August 24, 2020. We disclosed in our Current Report on Form 8-K dated October 30, 2020 that Mr. Chakoutis would not be returning to the Company. In April 2021, we appointed Peter Pellegrino as Interim Vice President of Finance and Mr. Pellegrino is our current principal accounting officer and principal financial officer.

Components of Operating Loss

Research and development expense. Research and development expense consists of salaries and related expenses, including share-based compensation, for personnel and contracted consultants and various materials and other costs to develop our new products, primarily: synthetic scaffolds, including investigation and development of materials and investigation and optimization of cellularization, autoseeders, and 3D bioreactors, as well as studies of cells and cell behavior. Other research and development expenses include the costs of outside service providers and material costs for prototype and test units and outside laboratories and testing facilities performing cell growth and materials experiments, as well as the costs of all other preclinical research and testing including animal studies and expenses related to potential patents. We expense research and development costs as incurred.

Selling, general and administrative expense. Selling, general and administrative expense consists primarily of salaries and other related expenses, including share-based compensation, for personnel in executive, accounting, information technology and human resources roles. Other costs include professional fees for legal and accounting services, insurance, investor relations and facility costs.

Other income (expense). Grant income reflects income earned under the SBIR grant. Grant income is recognized based on timing of when qualified research and development costs are incurred. Changes in fair value of warrant liability represent the change in the fair value of common stock warrants classified as liability awards during the three months March 31, 2021 and 2020. We use the Black-Scholes pricing model to value the related warrant liability. The costs associated with the issuance of the warrants have been recorded as an expense upon issuance.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are discussed in more detail in Note 2 to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.

Share-based Compensation

We account for our share-based compensation in accordance with the fair value recognition provisions of current authoritative guidance. Share-based awards, including stock options, are measured at fair value as of the grant date and recognized as expense over the requisite service period (generally the vesting period), which we have elected to amortize on a straight-line basis. Expense on share-based awards for which vesting is performance or milestone based is recognized on a straight-line basis from the date when we determine the achievement of the milestone is probable to the vesting/milestone achievement date. Since share-based compensation expense is based on awards ultimately expected to vest, it has been reduced by an estimate for future forfeitures. We estimate forfeitures at the time of grant and revise our estimate, if necessary, in subsequent periods. We estimate the fair value of options granted using the Black-Scholes option valuation model. Significant judgment is required in determining the proper assumptions used in these models. The assumptions used include the risk-free interest rate, expected term, expected volatility and expected dividend yield. We base our assumptions on historical data when available or, when not available, on a peer group of companies. However, these assumptions consist of estimates of future market conditions, which are inherently uncertain and subject to our judgment, and therefore any changes in assumptions could significantly impact the future grant date fair value of share-based awards.

Warrant Liability

Most of the warrants to purchase shares of our common stock have been classified on our condensed consolidated balance sheets as equity. We classify warrants as a liability in our condensed consolidated balance sheets if the warrant is a free-standing financial instrument that may require us to transfer cash consideration upon exercise and that cash transfer event would be out of our control. Such a “liability warrant” is initially recorded at fair value on the date of grant using the Black-Scholes model, net of issuance costs, and it is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the condensed consolidated statements of operations. We will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant.

Results of Operations

The following table summarizes the results of our operations for the three months ended March 31, 2021 and 2020 (in thousands):

	Three Months Ended March 31,						Change 2021 vs. 2020
	2021			2020			Change			%
Operating expenses
Research and development	$	473		$	643		$	(170	)		(26	)%
Selling, general and administrative		522			1,253			(731	)		(58	)%
Total operating expenses		995			1,896			(901	)		(48	)%

Other income (expense)
Grant Income		118			-			118			nm
Change in fair value of warrant liability		3			(100	)		103			103	%
Other income (expense), net		121			(100	)		221			221	%
Net loss	$	(874	)	$	(1,996	)	$	1,122			56	%

nm = not meaningful

Research and development expense

Research and development expense decreased approximately $0.2 million, or 24%, to $0.5 million for the three months ended March 31, 2021 as compared to $0.6 million for the same period in 2020. This decrease was due to lower headcount resulting in lower salary and share-based compensation expenses period over period.

Selling, general and administrative expense

Selling, general and administrative expense decreased approximately $0.7 million, or 59%, to $0.5 million for the three months ended March 31, 2021 compared to $1.3 million for the same period in 2020. This decrease was due to lower headcount resulting in lower salary expense of $0.3 million and lower share-based compensation expense of $0.4 million associated with the separation arrangement with our former Chief Executive Officer during the three months ended March 31, 2020.

Grant income

For the three months ended March 31, 2021, we recorded grant income of $0.1 million for qualified expenditures under the SBIR grant. There was no grant income for qualified expenditures from an SBIR grant for the three-month period ended March 31, 2020 as the modified Phase II grant development plan we submitted to the NICHD had not yet been approved as of March 31, 2020.

Change in fair value of warrant liability

During the three months ended March 31, 2021, the change in fair value of our warrant liability resulted in income of $4,000 due primarily to an increase in stock price and volatility of the underlying common shares. This compared to expense of $0.1 million for three months ended March 31, 2020 due to a higher stock price and volatility of the underlying common shares.

Liquidity and Capital Resources

Sources of liquidity. We have incurred operating losses since inception, and as of March 31, 2021, we had an accumulated deficit of approximately $69.8 million. We are currently investing significant resources in the development and commercialization of our products for use by clinicians and researchers in the fields of regenerative medicine and bioengineering. As a result, we expect to incur operating losses and negative operating cash flows for the foreseeable future.

The following table sets forth the primary uses of cash for the three months ended March 31, 2021 and 2020 (in thousands):

	Three Months Ended March 31,
	2021			2020
Net Cash Used in Operating Activities	$	(560	)	$	(1,094	)
Net Cash Used by Investing Activities	$	-		$	-
Net Cash Provided by Financing Activities	$	-		$	987

Comparison of Three Months Ended March 31, 2021 and 2020

Operating activities. Net cash used in operating activities of $0.6 million for the three months ended March 31, 2021 was due primarily to our net loss of $0.9 million, partially offset by a $0.2 million add-back for non-cash expenses including share-based compensation, depreciation, and change in fair value of warrant liability and $0.1 million of cash provided by working capital due to the timing of prepaid expenses and accounts payable.

Net cash used in operating activities of $1.1 million for the three months ended March 31, 2020 was primarily due to our net loss of $2.0 million, partially offset by $0.7 million add-back for non-cash expenses including share-based compensation, depreciation, and change in fair value of warrant liability, and $0.2 million of cash impact of working capital due to the timing of prepaid expenses and accounts payable.

Investing activities. There were no investing activities for the three months ended March 31, 2021 and 2020.

Financing activities. There were no financing activities for the three months ended March 31, 2021.

Net cash generated from financing activities during the three months ended March 31, 2020 of approximately $1.0 million consisted of $0.6 million of net proceeds received from private placement transactions that resulted in the issuance of 151,027 shares of our common stock and warrants to purchase 151,027 shares of common stock to a group of investors at an exercise price of $3.70 per share, and $0.4 million received from the issuance of 214,000 shares of our common stock to a group of investors in connection with the exercise of a portion of the warrants previously issued on December 27, 2017.

Off-Balance Sheet Arrangements

We do not have any material off-balance sheet arrangements as of March 31, 2021.

Other Information

JOBS Act

Effective December 31, 2020, we are no longer considered an “emerging growth company” under the Jumpstart Our Business Startups Act of 2012.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

The Company is a smaller reporting company and is not required to provide this information pursuant to Item 305(e), Regulation S-K.

Item 4.

Controls and Procedures.

This Report includes the certifications of our President (who is our principal executive officer) and our Interim Vice President of Finance (who is our principal financial and accounting officer) required by Rule 13a-14 of the Exchange Act. See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including the President and Interim Vice President of Finance, to allow timely decisions regarding required disclosures.

In connection with the preparation of this Quarterly Report on Form 10-Q, our management, under the supervision and with the participation of our President and Interim Vice President of Finance, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2021. Based upon the evaluation described above, our President and Interim Vice President of Finance have concluded that they believe our disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report on Form 10-Q due to the material weakness identified as of December 31, 2020 that has not yet been remediated.

Changes in Internal Control over Financial Reporting

Our management, with the participation of the President and Interim Vice President of Finance, has evaluated whether any change in our internal control over financial accounting and reporting occurred during the quarter ended March 31, 2021. During the period covered by this report, we have concluded that there were no changes during the fiscal quarter in our internal control over financial reporting, as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act, which have materially affected, or are reasonably likely to materially affect, our internal control over financial accounting and reporting.

Remediation Plan

As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on April 13, 2021, our management concluded that a material weakness in internal control over financial reporting existed as of December 31, 2020 and continues to exist as of March 31, 2021, being that we did not design or maintain effective internal controls over the timely identification and recording of financial statement adjustments. Specifically, we did not identify, analyze, record, and disclose certain non-routine accounting matters, such as a lease extension and a grant contract, timely and accurately. We are committed to remediating such material weaknesses in a timely fashion, including through the engagement of Point Providence Consulting and related appointment of Mr. Pellegrino as our Interim Vice President of Finance. As management continues to evaluate and work to improve its internal control over financial reporting, management may determine it is necessary to take additional measures to address the material weakness. Until the controls have been operating for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively, the material weakness described above will continue to exist.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time, we may be involved in various claims and legal proceedings arising in the ordinary course of business. Other than the ongoing civil lawsuit described in Item 3 of Part I of our Annual Report on Form 10-K filed with the SEC on April 13, 2021, there are no such matters pending that we expect to be material in relation to our business, financial condition, and results of operations or cash flows.

Item 1A.

Risk Factors

To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, and the additional risk factors noted below, there have been no material changes in the risk factors described in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on April 13, 2021.

Our audited financial statements for the year ended December 31, 2020 contain a going concern qualification. Our financial status creates doubt whether we will continue as a going concern. We will need additional funds in the near future and our operations will be adversely affected if we are unable to obtain needed funding.

We ended March 31, 2021 with approximately $0.5 million of operating cash on-hand and received cash proceeds of approximately $0.3 million in May of 2021 from existing investors. This will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2021. We will need to raise additional capital in the in or before the third quarter and beyond to fund operations. If we do not raise sufficient additional capital from outside sources in such timeframe, we will be forced to further curtail or cease our operations. Based on these circumstances, our ability to continue as a going concern is at risk and our independent registered public accounting firm included a “going concern” qualification as to our ability to continue as a going concern in their audit report dated April 13, 2021, included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on April 13, 2021. Our cash requirements and cash resources will vary significantly depending upon the timing, and the financial and other resources that will be required to complete ongoing development and pre-clinical and clinical testing of our products as well as regulatory efforts and collaborative arrangements necessary for our products that are currently under development. In addition to development and other costs, we expect to incur capital expenditures from time to time. These capital expenditures will be influenced by our regulatory compliance efforts, our success, if any, at developing collaborative arrangements with strategic partners, our needs for additional facilities and capital equipment and the growth, if any, of our business in general. We will require additional funding to continue our anticipated operations and support our capital and operating needs. We are currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. We may also pursue debt financings, other financing mechanisms, strategic collaborations and licensing arrangements. We may not be able to obtain additional financing on terms favorable to us, if at all. In addition, general market conditions, including the effect of the COVID-19 pandemic on financial markets, as well as the effects of laws and regulations on foreign investment in the United States under the jurisdiction of the Committee on Foreign Investment in the United States (CFIUS), and other agencies and related regulations, including the Foreign Investment Risk Review Modernization Act (FIRRMA), adopted in August 2018, may make it difficult for us to seek financing from the capital markets.

Any additional equity financings could result in significant dilution to our stockholders and possible restrictions on subsequent financings. Debt financing, if available, could result in agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring additional debt, making capital expenditures or paying dividends. Other financing mechanisms may involve selling intellectual property rights, payment of royalties or participation in our revenue or cash flow. In addition, in order to raise additional funds through strategic collaborations or licensing arrangements, we may be required to relinquish certain rights to some or all of our technologies or products. If we cannot raise funds or engage strategic partners on acceptable terms when needed, we may not be able to continue our research and development activities, develop or enhance our products, take advantage of future opportunities, grow our business, respond to competitive pressures or unanticipated requirements, or at worst may be forced to curtail or cease our operations.

Item 6.

Exhibits

Exhibit Index

31.1+		Certification of Interim Vice President of Finance of Biostage, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+		Certification of President of Biostage, Inc., pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Certification of Interim Vice President of Finance of Biostage, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of President of Biostage, Inc., pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by undersigned thereunto duly authorized.

Date: May 24, 2021

	BIOSTAGE, INC.

	By:	/s/ Hong Yu
		Name: Hong Yu
		Title: President (principal executive officer)

	By:	/s/ Peter A. Pellegrino Jr.
		Name: Peter A. Pellegrino Jr.
		Title: Interim Vice President of Finance (principal financial officer)

EX-31.1 2 tm2111640d1_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification

I, Peter A. Pellegrino Jr., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Biostage, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 24, 2021

	/s/ Peter A. Pellegrino Jr.
	Peter A. Pellegrino Jr.
	Interim Vice President of Finance

EX-31.2 3 tm2111640d1_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification

I, Hong Yu, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Biostage, Inc.;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 24, 2021

	/s/ Hong Yu
	Hong Yu
	President

EX-32.1 4 tm2111640d1_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF PERIODIC FINANCIAL REPORT

PURSUANT TO 18 U.S.C. SECTION 1350

The undersigned officer of Biostage, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (the “Report”) to which this certification is being furnished as an exhibit, as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. This certification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (Item 601(b)(32)) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act. In accordance with clause (ii) of Item 601(b) (32), this certification (A) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

Date: May 24, 2021

		/s/ Peter A. Pellegrino Jr.
	Name:	Peter A. Pellegrino Jr.
	Title:	Interim Vice President of Finance

EX-32.2 5 tm2111640d1_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF PERIODIC FINANCIAL REPORT

PURSUANT TO 18 U.S.C. SECTION 1350

Date: May 24, 2021

		/s/ Hong Yu
	Name:	Hong Yu
	Title:	President

EX-101.INS 6 bstg-20210331.xml XBRL INSTANCE DOCUMENT 0001563665 bstg:WarrantOneMember 2020-01-01 2020-03-31 0001563665 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0001563665 us-gaap:RetainedEarningsMember 2021-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001563665 us-gaap:RetainedEarningsMember 2020-12-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001563665 us-gaap:RetainedEarningsMember 2020-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001563665 us-gaap:RetainedEarningsMember 2019-12-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001563665 us-gaap:CommonStockMember 2021-03-31 0001563665 us-gaap:CommonStockMember 2020-12-31 0001563665 us-gaap:CommonStockMember 2020-03-31 0001563665 us-gaap:CommonStockMember 2019-12-31 0001563665 us-gaap:EmployeeStockOptionMember bstg:Biostage2013EquityIncentivePlanMember 2021-03-31 0001563665 us-gaap:EmployeeStockOptionMember bstg:Biostage2013EquityIncentivePlanMember 2020-12-31 0001563665 us-gaap:EmployeeStockOptionMember bstg:Biostage2013EquityIncentivePlanMember 2021-01-01 2021-03-31 0001563665 bstg:BiostageAmendedAndRestateEquityIncentivePlanMember 2020-06-30 0001563665 bstg:BiostageAmendedAndRestateEquityIncentivePlanMember 2020-06-01 2020-06-30 0001563665 bstg:Biostage2013EquityIncentivePlanMember 2021-01-01 2021-03-31 0001563665 srt:ChiefFinancialOfficerMember us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2020-02-29 0001563665 bstg:WarrantTwoMember 2020-01-01 2020-03-31 0001563665 us-gaap:InvestorMember us-gaap:SubsequentEventMember 2021-05-01 2021-05-31 0001563665 us-gaap:PrivatePlacementMember 2020-01-01 2020-03-31 0001563665 bstg:PaycheckProtectionProgramLoanMember 2020-12-18 2020-12-18 0001563665 bstg:PaycheckProtectionProgramLoanMember 2020-05-04 2020-05-04 0001563665 bstg:HarvardBiosciencePlanMember 2013-10-01 2013-10-31 0001563665 bstg:AssetsLeasedToOtherMember 2021-01-01 2021-03-31 0001563665 bstg:AssetsLeasedToOtherMember 2020-01-01 2020-03-31 0001563665 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001563665 bstg:PhaseTwoAwardMember 2020-08-03 0001563665 bstg:PhaseTwoAwardMember 2018-10-26 0001563665 2018-10-26 0001563665 us-gaap:FairValueInputsLevel2Member 2021-03-31 0001563665 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001563665 bstg:CommonStockAwardsMember 2020-03-31 0001563665 bstg:BiostageAmendedAndRestateEquityIncentivePlanMember 2021-01-01 2021-03-31 0001563665 bstg:PaycheckProtectionProgramLoanMember 2020-05-04 0001563665 bstg:BiostageAmendedAndRestateEquityIncentivePlanMember 2021-03-31 0001563665 bstg:WarrantOneMember 2020-03-31 0001563665 2019-12-31 0001563665 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001563665 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001563665 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001563665 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001563665 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001563665 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001563665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001563665 us-gaap:PerformanceSharesMember 2021-01-01 2021-03-31 0001563665 bstg:CommonStockAwardsMember 2020-03-01 2020-03-31 0001563665 us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2020-02-29 0001563665 2020-02-01 2020-02-29 0001563665 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001563665 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001563665 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001563665 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001563665 2021-05-21 0001563665 bstg:CommonStockAwardsMember 2020-03-27 2020-03-27 0001563665 bstg:WarrantTwoMember 2020-03-31 0001563665 us-gaap:PerformanceSharesMember 2021-03-31 0001563665 srt:ChiefFinancialOfficerMember 2020-02-01 2020-02-29 0001563665 bstg:CommonStockAwardsMember 2020-03-27 0001563665 2018-02-26 2018-03-28 0001563665 2020-03-31 0001563665 srt:MinimumMember 2021-01-01 2021-03-31 0001563665 srt:MaximumMember 2021-01-01 2021-03-31 0001563665 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001563665 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001563665 2018-10-26 2018-10-26 0001563665 bstg:PhaseTwoAwardMember 2021-01-01 2021-03-31 0001563665 2021-03-31 0001563665 2020-12-31 0001563665 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-01-01 2021-03-31 0001563665 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-01-01 2020-12-31 0001563665 us-gaap:MeasurementInputPriceVolatilityMember 2021-01-01 2021-03-31 0001563665 us-gaap:MeasurementInputPriceVolatilityMember 2020-01-01 2020-12-31 0001563665 us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-03-31 0001563665 us-gaap:MeasurementInputExpectedTermMember 2020-01-01 2020-12-31 0001563665 us-gaap:MeasurementInputExpectedDividendRateMember 2021-01-01 2021-03-31 0001563665 us-gaap:MeasurementInputExpectedDividendRateMember 2020-01-01 2020-12-31 0001563665 2021-01-01 2021-03-31 0001563665 2020-01-01 2020-03-31 xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:USD 100000 -3000 0.00 0.00 P1Y1M6D P10M24D 137.89 140.08 0.0012 0.0016 1.25 1.34 0 118000 100000 1400000 0 -55000 151 559000 558000 1000 91000 P180D P3Y6M P1Y 3.11 200000 <div> <div> 3.  Notes Payable On May 4, 2020, the Company obtained a loan (Loan) from the Bank of America (Lender) in the aggregate amount of $0.4 million, pursuant to the <a name="_Hlk71598023"></a>Paycheck Protection Plan (PPP), established as part of the CARES Act. The Loan is evidenced by a promissory note dated May 4, 2020 issued by the Company and will accrue interest at a fixed interest rate of 1% per annum from the funding date of May 4, 2020. Payments of principal and interest have been deferred  since the funding under the original terms of the promissory note. However, the Loan and accrued interest may be forgivable at the conclusion of this period. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The terms of the promissory note, including eligibility and forgiveness, may be subject to additional requirements adopted by the SBA. Any unforgiven portion of the PPP loan, including principal and interest, will mature on May 4, 2022 and will be required to be payable monthly. The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The Company has accounted for the loan under FASB ASC 470, Debt. Repayment amounts due within one year have been recorded as current liabilities, and the remaining amounts due in more than one year as long-term liabilities. On December 18, 2020, the Company submitted the loan forgiveness application for the entire borrowings of $0.4 million to the Lender and was notified on January 7, 2021 that the application was submitted to the Small Business Administration (SBA) for review. The SBA had up to 90 days from the date of submittal to make a final decision on loan forgiveness. The Company has yet to be notified of the SBA’s forgiveness decision. If the Company is successful in receiving forgiveness for any portion of the loan used for qualifying expenses, those amounts will be recorded as a gain upon extinguishment. <div /></div> </div> 15000 <div> <div> Recently Adopted Accounting Pronouncements Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption. <div /></div> </div> <div> <div> The following table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="middle" style="width:23.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the Quarter ended March 31 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance Sheet Classification </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Operating lease assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Right-of-use asset </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 166 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Liabilities: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Current operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Current portion of operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 105 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Non-current operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Operating lease liabilities, net of current portion </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 166 </td> </tr> </table></div>   <div /></div> </div> <div> <div> The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:24.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted average remaining lease term (in years) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.72 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.20 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average discount rate </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.24 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13.13 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   <div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 466 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 806 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and restricted cash as shown in the  statements of cash flows </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 516 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 856 </td> </tr> </table></div>   <div /></div> </div> 236970 0 214000 <div> <div> SBIR Award Grant income is recognized when qualified research and development costs are incurred and recorded in other income (expense), net in the consolidated statements of operations. When evaluating grant revenue from the SBIR grant, the Company considered accounting requirements under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts With Customers. The Company concluded that ASC 606 did not apply as there is no exchange of goods or services or an exchange of intellectual property between the parties; therefore, the Company presents grant income in other income. On March 28, 2018, the Company was awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testing of pediatric Cellspan<a name="_Hlk71596940"></a>™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 million of qualified research and development costs which was received and recognized as grant income during 2018. On October 26, 2018, the Company was awarded the Phase II  Fast-Track SBIR grant from the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinic through September 2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, the Company was awarded a third year of the Phase II grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualified expenses incurred from October 1, 2019 through September 30, 2020. In September of 2020, the Company filed and was granted a one year, no-cost extension for the Phase II grant period extending through September 30, 2021. For the three months ended March 31, 2021, the Company recognized $0.1 million of grant income, from Phase II of the SBIR grant. The aggregate SBIR grant to date provides a total award of $1.8 million, of which, approximately $1.4 million has been recognized through March 31, 2021. The Company did not recognize any grant income during the three months ended March 31, 2020. <div /></div> </div> 12 214 -24000 -24000 428000 426000 2000 5205 false --12-31 Q1 2021 2021-03-31 10-Q 0001563665 9388407 Yes false Non-accelerated Filer Yes Biostage, Inc. false true BSTG

31000

81000

317000

220000

69991000

70121000

588000

130000

588000

92000

496000

70000000

153000000

4000000

74800000

130000

800000

80000

50000

4237648

20000

1607570

2610078

3509335

1616134

1893201

2076000

1256000

1677000

926000

<div> <div> 1.  Overview and Basis of Presentation Overview Biostage, Inc. (Biostage or the Company) is a biotechnology company developing bioengineered organ implants based on the Company’s novel Cellframe ™ and Cellspan ™ technology. The Company’s technology is comprised of a proprietary biocompatible scaffold, which is the foundation of the Company’s Cellframe technology, that is seeded with the recipient’s own mesenchymal stromal cells to form the Company’s Cellspan implant. The Company believes that this technology may provide surgeons a new paradigm to address life-threatening conditions of the esophagus, bronchus, and trachea due to congenital abnormalities, diseases, infections and traumas. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. The Company has one business segment and does not have significant costs or assets outside the United States. On October 31, 2013, Harvard Bioscience, Inc. (Harvard Bioscience) contributed its regenerative medicine business assets, plus $15 million of cash, into Biostage (formerly “Harvard Apparatus Regenerative Technologies” at time of spin-off.) On November 1, 2013, the spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of all the shares of common stock of Biostage to stockholders of Harvard Bioscience (the “Distribution”). The Company’s common stock is currently traded on the OTCQB Venture Market under the symbol “BSTG”. Going Concern The Company has incurred substantial operating losses since its inception, and as of March 31, 2021 has an accumulated deficit of approximately $69.8 million and will require additional financing to fund future operations. The Company expects that its operating cash on-hand as of March 31, 2021 of $0.5 million, along with cash proceeds of approximately $0.3 million received in May of 2021 from existing investors, will enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2021. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company will need to raise additional funds to fund its operations. In the event the Company does not raise additional capital from outside sources in the second quarter, it may be forced to curtail or cease its operations. Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of products, as well as regulatory efforts and collaborative arrangements necessary for the Company’s products that are currently under development. The Company is currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorable terms, if at all. The Company’s operations will be adversely affected if it is unable to raise or obtain needed funding and such circumstance may materially affect the Company’s ability to continue as a going concern.   The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty. Basis of Presentation The consolidated financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). Use of Estimates The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, expenses and related disclosures. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of expenses. Actual results may differ from these estimates. Net Loss Per Share Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including the assumed exercise of stock options, warrants, and the impact of unvested restricted stock. The Company applies the two-class method to calculate basic and diluted net loss per share attributable to common stockholders as its warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. However, the two-class method does not impact the net loss per share of common stock as the Company has been in a net loss position and the warrant holders do not participate in losses. Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred. Unaudited Interim Financial Information The accompanying interim consolidated balance sheet as of  March 31, 2021, consolidated interim statements of operations and stockholders’ equity for the three months ended March 31, 2021 and 2020, and consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2021, its consolidated results of operations, consolidated statement of cash flows, and consolidated stockholders’ equity for the three-month periods ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three-month periods ended March 31, 2021 and 2020 are unaudited. The results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period. <div /></div> </div>

500000

466000

<div> <div> Restricted Cash Restricted cash consists of $50,000 held as collateral for the Company’s credit card program as of March 31, 2021 and December 31, 2020. The Company’s statements of cash flows include restricted cash with cash when reconciling the beginning-of-period and end-of-period total amounts shown on such statements. A reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statements of cash flows is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 466 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 806 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and restricted cash as shown in the  statements of cash flows </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 516 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 856 </td> </tr> </table></div>   <div /></div> </div>

963000

856000

516000

-107000

-560000

3.70

2.00

8.00

151027

92212

<div> <div> 7.  Commitments and Contingencies On April 14, 2017, representatives for the estate of a deceased individual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company and Harvard Bioscience. The complaint alleges that the decedent’s injury and death were caused by two tracheal implants that incorporated synthetic trachea scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in two surgeries performed in 2012 and 2013. The civil complaint seeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuit relates to the Company’s first-generation trachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Cellspan technology nor to its lead development product candidate, the Cellspan Esophageal Implant. The Company intends to vigorously defend this case. While the Company believes that such claim lacks merit, the Company is unable to predict the ultimate outcome of such litigation. In accordance with a separation and distribution agreement between Harvard Bioscience and the Company relating to the spin-off, the Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer as a result of this litigation. The Company has been informed by its insurance provider that the case has been accepted as an insurable claim under the Company’s product liability insurance policy. The Company does not believe a loss is probable at this time and therefore has not accrued any amounts for this contingent liability. From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. Other than the above matter, there are no such matters pending that the Company expects to be material in relation to its business, financial condition, results of operations, or cash flows. <div /></div> </div>

3461091

0.01

60000000

9388407

94000

0.01

48000

43000

17000

14000

<div> <div> 6.  Share-Based Compensation Biostage Amended and Restated Equity Incentive Plan The Company maintains the Amended and Restated Equity Incentive Plan (the Plan) for the benefit of certain officers, employees, non-employee directors, and other key persons (including consultants and advisory board members). All options and awards granted under the Plan consist of the Company’s shares of common stock. The Company’s policy is to issue stock available from its registered but unissued stock pool through its transfer agent to satisfy stock option exercises and the vesting of restricted stock units. The vesting period for awards is generally four years and the contractual life is ten years. Canceled and forfeited options and awards are available to be reissued under the Plan. In June 2020, the Company’s shareholders approved the Plan to, among other things, increase of the number of shares of the Company’s common stock available for issuance pursuant thereto by 3,000,000 shares, which increased the total shares authorized to be issued under the Plan to 5,098,000. There were 3,461,091 shares available for issuance as of March 31, 2021. The Company has granted options to purchase common stock under the Plan. Stock option activity during the three months ended March 31, 2021 was as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:25.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Options </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted – </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> exercise price </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,599,720 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.33 </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 16,413 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.80 </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding at March 31, 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,616,134 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.31 </td> </tr> </table></div>   The Company’s outstanding stock options include 338,663 performance-based awards that have vesting provisions subject to the achievement of certain business milestones. Total unrecognized compensation expense for the remaining 243,532 performance-based awards is approximately $0.8 million. No expense has been recognized for these unvested awards as of March 31, 2021 given that the milestone achievements for these awards have not yet been deemed probable for accounting purposes. Aggregate intrinsic value for outstanding options and exercisable options for the year ended March 31, 2021 was $0 based on the Company’s closing stock price of $1.34 per share as of March 31, 2021. As of March 31, 2021, unrecognized compensation cost related to unvested nonperformance-based awards amounted to $0.3 million, which will be recognized over a weighted average period of 0.3 years. The Company uses the Black-Scholes option pricing model to value its stock options. The weighted average assumptions for valuing options granted during the three months ended March 31, 2021 were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.47 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 123.20 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.3 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> n/a </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   In February 2020, as part of the termination arrangement with the Company’s former chief executive officer, the Company modified certain options to purchase 236,970 shares of common stock, issued an 80,000 fully vested stock option grant, and accelerated the vesting of 3,300 restricted stock units resulting in recording $153,000,  $70,000, and $4,000, respectively, of share-based compensation during the three months ended March 31, 2020. In March 2020, the Company issued 35,000 common stock awards to an employee that was earned upon the achievement of certain milestones. One of the milestones for 15,000 common shares was achieved on March 27, 2020, and the Company issued 9,795 fully vested share of common stock to the employee with 5,205 common shares withheld to cover taxes. During the three months ended March 31, 2020, the Company recognized a total of $74,800 of share-based compensation with the remaining expense of $65,200 recognized upon the achievement of certain milestones over the requisite service period during the three months ended June 30, 2020. The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31, </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 92 </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 496 </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total share-based compensation </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 130 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 588 </td> </tr> </table></div>   The Company estimates the fair value of non-employee share options using the Black-Scholes option pricing model reflecting the same assumptions as applied to employee and director options in each of the reporting periods, other than the expected life, which is assumed to be the remaining contractual life of the options. <div /></div> </div>

-0.24

-0.09

<div> <div> 9.  Net Loss Per Share Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding. The following potential common shares were excluded from the calculation of diluted net loss per share attributable to common stockholders for the three months ended March 31, 2021 and 2020 because including them would have had an anti-dilutive effect:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:28.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31,  </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants to purchase common stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,893,201 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,610,078 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options to purchase common stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,616,134 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,607,570 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock awards </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,000 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,509,335 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,237,648 </td> </tr> </table></div>   <div /></div> </div>

300000

P3M18D

65200000

100000

-3000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.16 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.12 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 140.08 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 137.89 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.9 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.1 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.00 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.00 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Market value of common stock </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.34 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.25 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants to purchase shares of common stock </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 92,212 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 92,212 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> </table></div>   <div /></div> </div>

<div> <div> 5.  Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes a valuation hierarchy for disclosure of the inputs to the valuations used to measure fair value that prioritizes the inputs into three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company had no assets or liabilities classified as Level 2 as of March 31, 2021 and December 31, 2020. The Company’s restricted cash that serves as collateral for the Company’s credit card program is held in a demand money market account and is measured at fair value based on quoted prices, which are Level 1 inputs. The Company classifies warrants to purchase common stock that are accounted for as liabilities as Level 3 liabilities, as discussed below. The following table presents a reconciliation of the Company’s liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three months ended March 31, 2021:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:82.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:82.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrant Liability </td> </tr> <tr> <td valign="bottom" style="width:82.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:15.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> </tr> <tr> <td valign="bottom" style="width:82.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17 </td> </tr> <tr> <td valign="bottom" style="width:82.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Change in fair value upon re-measurement </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> </tr> <tr> <td valign="bottom" style="width:82.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at March 31, 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14 </td> </tr> </table></div>   The Company has re-measured the warrant liability to estimated fair value at inception, prior to modification and at each reporting date using the Black-Scholes option pricing model with the following weighted average assumptions:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.16 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.12 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 140.08 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 137.89 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term (in years) </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.9 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.1 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.00 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.00 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Market value of common stock </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.34 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.25 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:72.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants to purchase shares of common stock </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 92,212 </td> <td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 92,212 </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> </table></div>   <div /></div> </div>

-3000

17000

14000

1800000

1100000

500000

<div> <div> 10.  Income Taxes The Company did not record a federal or state income tax provision or benefit for the three months ended March 31, 2021 and 2020, respectively, due to the expected loss before income taxes to be incurred for the years ended December 31, 2021 and 2020, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets. <div /></div> </div>

-14000

50000

82000

-97000

-98000

-136000

<div> <div> The Company recorded lease expense in the following expense categories of its consolidated statements of operations:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="4" valign="bottom" style="width:27.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the Three Months   </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:27.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ended March 31, </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Statement of Operations Classification </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Operating lease expense </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19 </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11 </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 30 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 30 </td> </tr> </table></div>   <div /></div> </div>

false

<div> <div> The minimum lease payments for the next five years are expected to be as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As Of  </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 91 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  7 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2024 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 172 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: imputed interest </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 16 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Present value of operating lease liabilities </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> </tr> </table></div>   <div /></div> </div>

172000

12000

7000

62000

16000

P1Y

<div> <div> 8.  Leases The Company leases laboratory and office space and certain equipment with remaining terms ranging approximately from 1 year to 3.5 years. The laboratory and office space arrangement is under a sublease that was renewed in December of 2020 and currently extends through May 31, 2022. This lease automatically renews annually for a one-year period unless the Company or the counterparty provides a notice of termination within one hundred and eighty days prior to May 31 of each year. All of the Company’s leases qualify as operating leases. The following table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="middle" style="width:23.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the Quarter ended March 31 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Balance Sheet Classification </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Assets: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Operating lease assets </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Right-of-use asset </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 166 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Liabilities: </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Current operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Current portion of operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 110 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 105 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Non-current operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Operating lease liabilities, net of current portion </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 46 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61 </td> </tr> <tr> <td valign="bottom" style="width:33.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total operating lease liabilities </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:39.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 156 </td> <td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 166 </td> </tr> </table></div>   Cash paid included in the computation of the right of use asset and lease liability during the three months ended March 31, 2021 and 2020 amounted to approximately $30,000,  respectively. The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:24.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As of March 31, </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Weighted average remaining lease term (in years) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1.72 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.20 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:71.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average discount rate </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 10.24 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> <td valign="bottom" style="width:11.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 13.13 </td> <td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> </table></div>   The Company recorded lease expense in the following expense categories of its consolidated statements of operations:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="4" valign="bottom" style="width:27.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> For the Three Months   </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:27.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Ended March 31, </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Statement of Operations Classification </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Operating lease expense </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 19 </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Selling, general and administrative </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 11 </td> </tr> <tr> <td valign="bottom" style="width:25.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:37.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 30 </td> <td valign="bottom" style="width:03.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 30 </td> </tr> </table></div>   The minimum lease payments for the next five years are expected to be as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> As Of  </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 91 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 62 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 12 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  7 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2024 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 172 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: imputed interest </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 16 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Present value of operating lease liabilities </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> </tr> </table></div>   <div /></div> </div>

951000

875000

2076000

1256000

756000

771000

120000

58000

987000

-1094000

-560000

-1996000

-874000

-100000

121000

284000

346000

1896000

995000

-1896000

-995000

30000

166000

156000

105000

107000

110000

us-gaap:OperatingLeaseLiabilityCurrent

61000

75000

46000

us-gaap:OperatingLeaseLiabilityNoncurrent

30000000

166000

182000

156000

us-gaap:OperatingLeaseRightOfUseAsset

0.1313

0.0000

P2Y2M12D

P0Y0M

0.01

2000000

524000

388000

15000000

400000

559000

428000

600000

300000

400000

217000

174000

643000

19000

473000

19000

50000

-68960000

-69834000

-69800000

<div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:28.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31,  </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Warrants to purchase common stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,893,201 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,610,078 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Options to purchase common stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,616,134 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,607,570 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Common stock awards </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 20,000 </td> </tr> <tr> <td valign="bottom" style="width:69.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3,509,335 </td> <td valign="bottom" style="width:02.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,237,648 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended March 31, </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:31.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 80 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 92 </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 496 </td> </tr> <tr> <td valign="bottom" style="width:65.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total share-based compensation </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 130 </td> <td valign="bottom" style="width:02.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 588 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The Company has granted options to purchase common stock under the Plan. Stock option activity during the three months ended March 31, 2021 was as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:25.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stock Options </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted – </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> average </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> exercise price </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding at December 31, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,599,720 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.33 </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 16,413 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.80 </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Canceled </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding at March 31, 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,616,134 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.31 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The Company uses the Black-Scholes option pricing model to value its stock options. The weighted average assumptions for valuing options granted during the three months ended March 31, 2021 were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.47 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 123.20 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 5.3 </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> <tr> <td valign="bottom" style="width:82.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> n/a </td> <td valign="bottom" style="width:05.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.88 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106.7 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> months </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.70 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Market value of common stock </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.11 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   <div /></div> </div>

1253000

11000

522000

11000

588000

130000

3300

P4Y

35000

9795

P10Y

3.70

0.00

P2M

P5Y3M18D

1.067

1.2320

0.0088

0.0047

3000000

243532

5098000

16413000

1599720000

338663

1616134000

6.33

6.31

1.80

3.70

1.34

8156

8533

9388

<div> <div> 2.  Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10‑K. SBIR Award Grant income is recognized when qualified research and development costs are incurred and recorded in other income (expense), net in the consolidated statements of operations. When evaluating grant revenue from the SBIR grant, the Company considered accounting requirements under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts With Customers. The Company concluded that ASC 606 did not apply as there is no exchange of goods or services or an exchange of intellectual property between the parties; therefore, the Company presents grant income in other income. On March 28, 2018, the Company was awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the Eunice Kennedy National Institute of Child Health and Human Development (NICHD) to support testing of pediatric Cellspan<a name="_Hlk71596940"></a>™ Esophageal Implants (CEIs). The award for Phase I provided for the reimbursement of approximately $0.2 million of qualified research and development costs which was received and recognized as grant income during 2018. On October 26, 2018, the Company was awarded the Phase II  Fast-Track SBIR grant from the Eunice Kennedy NICHD grant aggregating $1.1 million to support development, testing, and translation to the clinic through September 2019 and represented years one and two of the Phase II portion of the award. On August 3, 2020, the Company was awarded a third year of the Phase II grant totaling $0.5 million for support of development, testing, and translation to the clinic covering qualified expenses incurred from October 1, 2019 through September 30, 2020. In September of 2020, the Company filed and was granted a one year, no-cost extension for the Phase II grant period extending through September 30, 2021. For the three months ended March 31, 2021, the Company recognized $0.1 million of grant income, from Phase II of the SBIR grant. The aggregate SBIR grant to date provides a total award of $1.8 million, of which, approximately $1.4 million has been recognized through March 31, 2021. The Company did not recognize any grant income during the three months ended March 31, 2020. Restricted Cash Restricted cash consists of $50,000 held as collateral for the Company’s credit card program as of March 31, 2021 and December 31, 2020. The Company’s statements of cash flows include restricted cash with cash when reconciling the beginning-of-period and end-of-period total amounts shown on such statements. A reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statements of cash flows is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> March 31,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:24.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> (In thousands) </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 466 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 806 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Restricted cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 50 </td> </tr> <tr> <td valign="bottom" style="width:73.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total cash and restricted cash as shown in the  statements of cash flows </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 516 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 856 </td> </tr> </table></div>   Recently Adopted Accounting Pronouncements Accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s financial statements upon adoption. <div /></div> </div>

1089000

65102000

82000

-64095000

644000

66650000

85000

-66091000

1125000

69991000

94000

-68960000

381000

70121000

94000

-69834000

<div> <div> 4.  Capital Stock During the three months ended March 31, 2020, the Company issued a total of 151,027 shares of our common stock at a purchase price of $3.70 per share and warrants to purchase 151,027 shares of common stock at an exercise price of $3.70 per share to a group of investors for aggregate gross and net proceeds of approximately $0.6 million, of which, $0.5 million and $0.1 million was allocated to the common stock and warrants, respectively. The Company has classified these warrants on its consolidated balance sheets as equity and valued using the Black-Scholes model based on the following weighted average assumptions:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Risk-free interest rate </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.88 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106.7 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected term </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> months </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividend yield </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.70 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:77.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Market value of common stock </td> <td valign="bottom" style="width:02.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.11 </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> </table></div>   During the three months ended March 31, 2020, the Company also issued 214,000 shares of our common stock to a group of investors in connection with the exercise of 214,000 previously issued warrants at $2.00 per share for aggregate gross and net proceeds of approximately $0.4 million. During the three months ended March 31, 2020, the Company issued a total of 11,950 shares of our common stock to employees due to the vesting of restricted stock units and issuance of a common stock award. <div /></div> </div>

214000

100000

11950

151027

80000000

<div> <div> 11.  Subsequent Events Equity Transactions In May 2021, the Company received aggregate gross and net proceeds of approximately $0.3 million from a group of existing investors. <div /></div> </div>

77000

22000

500000

8287

9388

EX-101.SCH 7 bstg-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Cash and restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Leases - Operating leases in consolidated balance sheets (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Leases - Operating lease expense (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Leases - Minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Leases - Minimum lease paymentss (Details)(calc 2) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Overview and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Capital Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Capital Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Fair Value Measurements - Reconciliation of company liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Fair Value Measurements - Weighted average assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Share-Based Compensation - Stock option and restricted stock unit activity (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Share-Based Compensation - Weighted average assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Share-Based Compensation - Share-based compensation expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Net loss Per Share - Anti-dilutive shares (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Overview and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Capital Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Leases - Weighted average discount rate and lease term (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bstg-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bstg-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bstg-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document Type Document Period End Date Entity Registrant Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Trading Symbol CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash Cash Restricted Cash, Current Restricted cash Restricted cash Unbilled Contracts Receivable Grant receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net. Property, plant and equipment, net Operating Lease, Right-of-Use Asset Operating lease assets Right-of-use assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities and Other Liabilities Accrued and other current liabilities Notes Payable, Current Current portion of notes payable Derivative Liability, Current Warrant liability Operating Lease, Liability, Current Current portion of operating lease liability Current portion of operating lease liabilities Liabilities, Current Total current liabilities Notes Payable, Noncurrent Notes payable, net of current portion Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Non-current Operating lease liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.01 par value; 2,000,000 shares authorized as of March 31, 2021 and December 31, 2020, 0 issued and outstanding Common Stock, Value, Issued Common stock, par value $0.01 per share, 60,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 9,388,407 issued and outstanding at March 31, 2021 and December 31, 2020 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Balance Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONSOLIDATED STATEMENTS OF OPERATIONS Revenues Revenues Operating Expenses [Abstract] Operating expenses: Research and development Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Selling, general and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Other Nonoperating Income (Expense) [Abstract] Other income (expense): The amount of grant income which is recognized based on timing of when qualified research and development costs are incurred and recorded and classified as grant income in other income (expense), net. Grant Income Grant income Fair Value Adjustment of Warrants Change in fair value of warrant liability Nonoperating Income (Expense) Total other income (expense), net Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Earnings Per Share, Basic and Diluted Basic and diluted net loss per share Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average common shares, basic and diluted CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Balance (in shares) Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Share-based compensation Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture Share-based compensation (in shares) Number of fully vested stock options issued Value of stock of share issued during period attributable to fully vested common stock awards. Stock Issued During Period, Value, Fully Vested Common Stock Awards Issuance of fully vested common shares Number of shares of stock issued during period attributable to fully vested common stock awards. Stock Issued During Period, Shares, Fully Vested Common Stock Awards Issuance of fully vested common shares (in shares) The information pertaining to issuance of common stock and warrants to purchase common stock value, net of offering costs. Issuance of Common Stock And Warrants To Purchase Common Stock Value, Net of Offering Costs Issuance of common stock, and warrants to purchase common stock The information pertaining to issuance of common stock and warrants to purchase common stock share, net of offering costs. Issuance of Common Stock And Warrants To Purchase Common Stock Share, Net of Offering Costs Issuance of common stock, and warrants to purchase common stock (in shares) It represents the amount of stock issued during period value of common stock upon warrant exercises Stock Issued During Period Value Of Common Stock Upon Warrant Exercises Issuance of common stock from exercise of warrants Number of shares issued during the period common stock upon warrant exercises. Stock Issued During Period Shares Of Common Stock Upon Warrant Exercises Issuance of common stock from exercise of warrants (in shares) CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] OPERATING ACTIVITIES Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation. Share-based compensation expense Depreciation Depreciation Gross amount of expense (income) related to adjustment to fair value of warrant liability before deducting issuance cost. Fair Value Adjustment Of Warrants Gross Change in fair value of warrant liability Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: The increase (decrease) during the reporting period pertaining to grant receivables. Increase (Decrease) in Grant Receivables Grant receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other current liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] FINANCING ACTIVITIES Proceeds from Issuance of Private Placement Proceeds from issuance of common stock and warrants Proceeds from Issuance of Warrants Proceeds from exercise of warrants Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and restricted cash at end of period Cash and restricted cash at beginning of period Total cash and restricted cash as shown in the consolidated statements of cash flows No definition. Overview and Basis of Presentation Business Description and Basis of Presentation [Text Block] Overview and Basis of Presentation Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Notes Payable The entire disclosure on notes payable. Notes Payable [Text Block] Notes Payable Capital Stock Stockholders' Equity Note Disclosure [Text Block] Capital Stock Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Compensation Commitments and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Leases Lessee, Operating Lease, Disclosure [Table Text Block] Leases Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Income Taxes Income Tax Disclosure [Text Block] Income Taxes Subsequent Events Subsequent Events [Text Block] Subsequent Events Small Business Innovation Research (SBIR) grant by the Human Development to support testing of pediatric Cellspan Esophageal Implants. Small Business Innovation Research [Policy Text Block] SBIR Award Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Disclosure of accounting policy pertaining to newly adopted accounting pronouncements. Recently Adopted Accounting Pronouncements [Policy Text Block] Recently Adopted Accounting Pronouncements Tabular disclosure for reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statements of cash flows. Schedule Of Reconciliation Of Cash And Restricted Cash Reported Within Balance Sheet That Sum To Total Of Same Amounts Shown In Cash Flow Statement [Table Text Block] Schedule of reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the consolidated statements of cash flows Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Classification of warrants to equity Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of reconciliation company's liabilities at fair value on recurring basis Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of weighted average assumptions Share-based Compensation, Activity [Table Text Block] Schedule of Stock option and restricted stock unit activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of share-based compensation expense Table depicting details of the lessees right to asset utilization under operating lease corresponding to The relevant liability undiscounted Right To Use Of Asset And Liability In Respect Of Operating Leases [Table Text Block] Summary of presentation of operating leases in consolidated balance sheets Tabular disclosure of discount rate and remaining lease term of operating and financial leases. Schedule Of Discount Rate And Lease Term Used In Calculating Lease Liabilities And Assets [Table Text Block] Schedule of Weighted average discount rate and lease term Lease, Cost [Table Text Block] Summary of lease expense categories in consolidated statements of operations Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Summary of minimum lease payments for the next five years and thereafter Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of antidilutive securities excluded from computation of earnings per share Overview And Basis Of Presentation [Table] Overview And Basis Of Presentation [Line Items] Proceeds from Contributions from Parent Proceeds from Issuance or Sale of Equity Gross and net proceeds from issuance Cash proceeds received Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Basic And Diluted Earnings Per Share [Line Items] Amount of cash inflow for recognized grants. Grants Receivable, Recognized Recognized grants receivable Restricted Cash Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period It represents the maximum research and development expenses reimbursement. Maximum Research And Development Expenses Reimbursement Grants Receivable, Current Grants Receivable in fiscal year Grants Receivable The amount of grant income recognized. Grant Income Recognized Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Proceeds from Issuance of Debt Debt Instrument, Interest Rate, Stated Percentage Fixed interest rate Schedule of Stock by Class [Table] Class of Stock [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Expected term (in months) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Exercise price The value represents market value of common stock. Market Value Of Common Stock Market value of common stock Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Security that gives the holder the right to purchase shares of warrant one in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrant One [Member] Warrant One [Member] Security that gives the holder the right to purchase shares of warrant two in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrant Two [Member] Warrant Two [Member] Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Restricted Stock [Member] Restricted Stock [Member] Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] Private Placement [Member] Private Placement [Member] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price Proceeds from Warrant Exercises Stock Issued During Period, Shares, New Issues Share Price Shares issued Pursuant to Exercise of Warrants By the Holders Of The Warrants Shares Issued As A Result Of Exercise Of Warrants Warrants and Rights Outstanding Stock Issued During Period, Value, New Issues Ending Balance Ending Balance Beginning Balance Liabilities classified Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Change in fair value upon re-measurement Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Assets, Fair Value Disclosure [Abstract] Assets: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Assets classified Liabilities, Fair Value Disclosure [Abstract] Liabilities: Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] EX-101.PRE 11 bstg-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	May 21, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Entity Registrant Name	Biostage, Inc.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		9,388,407
Entity Central Index Key	0001563665
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Trading Symbol	BSTG

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 466
Restricted cash	50	$ 50
Grant receivable	22	77
Prepaid expenses and other current assets	388	524
Total current assets	926	1,677
Property, plant and equipment, net	174	217
Right-of-use assets	156	182
Total assets	1,256	2,076
Current liabilities:
Accounts payable	81	31
Accrued and other current liabilities	220	317
Current portion of notes payable	346	284
Warrant liability	14	17
Current portion of operating lease liability	110	107
Total current liabilities	771	756
Notes payable, net of current portion	58	120
Operating lease liability, net of current portion	46	75
Total liabilities	875	951
Commitments and contingencies (Note)
Stockholders' equity:
Preferred stock, $0.01 par value; 2,000,000 shares authorized as of March 31, 2021 and December 31, 2020, 0 issued and outstanding	0	0
Common stock, par value $0.01 per share, 60,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 9,388,407 issued and outstanding at March 31, 2021 and December 31, 2020	94	94
Additional paid-in capital	70,121	69,991
Accumulated deficit	(69,834)	(68,960)
Total stockholders' equity	381	1,125
Total liabilities and stockholders' equity	$ 1,256	$ 2,076

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	9,388,407	9,388,407
Common stock, shares outstanding	9,388,407	9,388,407

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 0
Operating expenses:
Research and development	473	643
Selling, general and administrative	522	1,253
Total operating expenses	995	1,896
Operating loss	(995)	(1,896)
Other income (expense):
Grant income	118	0
Change in fair value of warrant liability	3	(100)
Total other income (expense), net	121	(100)
Net loss	$ (874)	$ (1,996)
Basic and diluted net loss per share	$ (0.09)	$ (0.24)
Weighted-average common shares, basic and diluted	9,388	8,287

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 82,000	$ 65,102,000	$ (64,095,000)	$ 1,089,000
Balance (in shares) at Dec. 31, 2019	8,156
Net loss			(1,996,000)	(1,996,000)
Share-based compensation		588,000		588,000
Issuance of fully vested common shares		(24,000)		(24,000)
Issuance of fully vested common shares (in shares)	12
Issuance of common stock, and warrants to purchase common stock	$ 1,000	558,000		559,000
Issuance of common stock, and warrants to purchase common stock (in shares)	151
Issuance of common stock from exercise of warrants	$ 2,000	426,000		428,000
Issuance of common stock from exercise of warrants (in shares)	214
Balance at Mar. 31, 2020	$ 85,000	66,650,000	(66,091,000)	644,000
Balance (in shares) at Mar. 31, 2020	8,533
Balance at Dec. 31, 2020	$ 94,000	69,991,000	(68,960,000)	1,125,000
Balance (in shares) at Dec. 31, 2020	9,388
Net loss	$ 0	0	(874,000)	(874,000)
Share-based compensation	$ 0	130,000	0	130,000
Share-based compensation (in shares)	0
Balance at Mar. 31, 2021	$ 94,000	$ 70,121,000	$ (69,834,000)	$ 381,000
Balance (in shares) at Mar. 31, 2021	9,388

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING ACTIVITIES
Net loss	$ (874)	$ (1,996)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	130	588
Depreciation	43	48
Change in fair value of warrant liability	(3)	100
Changes in operating assets and liabilities:
Grant receivable	55	0
Prepaid expenses and other current assets	136	98
Accounts payable	50	(14)
Accrued and other current liabilities	(97)	82
Net cash used in operating activities	(560)	(1,094)
INVESTING ACTIVITIES
Net cash used in investing activities	0	0
FINANCING ACTIVITIES
Proceeds from issuance of common stock and warrants	0	559
Proceeds from exercise of warrants	0	428
Net cash provided by financing activities	0	987
Net decrease in cash and restricted cash	(560)	(107)
Cash and restricted cash at beginning of period		963
Cash and restricted cash at end of period	$ 516	$ 856

XML 18 R7.htm IDEA: XBRL DOCUMENT

Overview and Basis of Presentation	3 Months Ended
Overview and Basis of Presentation	Mar. 31, 2021
Overview and Basis of Presentation
Overview and Basis of Presentation	1. Overview and Basis of Presentation Overview Biostage, Inc. (Biostage or the Company) is a biotechnology company developing bioengineered organ implants based on the Company’s novel Cellframe ™ and Cellspan ™ technology. The Company’s technology is comprised of a proprietary biocompatible scaffold, which is the foundation of the Company’s Cellframe technology, that is seeded with the recipient’s own mesenchymal stromal cells to form the Company’s Cellspan implant. The Company believes that this technology may provide surgeons a new paradigm to address life-threatening conditions of the esophagus, bronchus, and trachea due to congenital abnormalities, diseases, infections and traumas. Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and acquiring operating assets. The Company has one business segment and does not have significant costs or assets outside the United States. On October 31, 2013, Harvard Bioscience, Inc. (Harvard Bioscience) contributed its regenerative medicine business assets, plus $15 million of cash, into Biostage (formerly “Harvard Apparatus Regenerative Technologies” at time of spin-off.) On November 1, 2013, the spin-off of the Company from Harvard Bioscience was completed. On that date, the Company became an independent company that operates the regenerative medicine business previously owned by Harvard Bioscience. The spin-off was completed through the distribution of all the shares of common stock of Biostage to stockholders of Harvard Bioscience (the “Distribution”). The Company’s common stock is currently traded on the OTCQB Venture Market under the symbol “BSTG”. Going Concern The Company has incurred substantial operating losses since its inception, and as of March 31, 2021 has an accumulated deficit of approximately $69.8 million and will require additional financing to fund future operations. The Company expects that its operating cash on-hand as of March 31, 2021 of $0.5 million, along with cash proceeds of approximately $0.3 million received in May of 2021 from existing investors, will enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2021. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company will need to raise additional funds to fund its operations. In the event the Company does not raise additional capital from outside sources in the second quarter, it may be forced to curtail or cease its operations. Cash requirements and cash resource needs will vary significantly depending upon the timing of the financial and other resource needs that will be required to complete ongoing development, pre-clinical and clinical testing of products, as well as regulatory efforts and collaborative arrangements necessary for the Company’s products that are currently under development. The Company is currently seeking and will continue to seek financings from other existing and/or new investors to raise necessary funds through a combination of public or private equity offerings. The Company may also pursue debt financings, other financing mechanisms, research grants, or strategic collaborations and licensing arrangements. The Company may not be able to obtain additional financing on favorable terms, if at all. The Company’s operations will be adversely affected if it is unable to raise or obtain needed funding and such circumstance may materially affect the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and therefore, the consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amount and classifications of liabilities that may result from the outcome of this uncertainty. Basis of Presentation The consolidated financial statements reflect the Company’s financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). Use of Estimates The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, expenses and related disclosures. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of expenses. Actual results may differ from these estimates. Net Loss Per Share Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including the assumed exercise of stock options, warrants, and the impact of unvested restricted stock. The Company applies the two-class method to calculate basic and diluted net loss per share attributable to common stockholders as its warrants to purchase common stock are participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. However, the two-class method does not impact the net loss per share of common stock as the Company has been in a net loss position and the warrant holders do not participate in losses. Basic and diluted shares outstanding are the same for each period presented as all common stock equivalents would be antidilutive due to the net losses incurred. Unaudited Interim Financial Information The accompanying interim consolidated balance sheet as of March 31, 2021, consolidated interim statements of operations and stockholders’ equity for the three months ended March 31, 2021 and 2020, and consolidated statements of cash flows for the three months ended March 31, 2021 and 2020 are unaudited. The interim unaudited consolidated financial statements have been prepared in accordance with GAAP on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments necessary for a fair statement of the Company’s financial position as of March 31, 2021, its consolidated results of operations, consolidated statement of cash flows, and consolidated stockholders’ equity for the three-month periods ended March 31, 2021 and 2020. The financial data and other information disclosed in these notes related to the three-month periods ended March 31, 2021 and 2020 are unaudited. The results for the three months ended March 31, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods or any future year or period.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies

SBIR Award

Grant income is recognized when qualified research and development costs are incurred and recorded in other income (expense), net in the consolidated statements of operations. When evaluating grant revenue from the SBIR grant, the Company considered accounting requirements under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts With Customers. The Company concluded that ASC 606 did not apply as there is no exchange of goods or services or an exchange of intellectual property between the parties; therefore, the Company presents grant income in other income.

The Company did not recognize any grant income during the three months ended March 31, 2020.

Restricted Cash

A reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statements of cash flows is as follows:


	March 31,		December 31,
	2021		2020
	(In thousands)
Cash	$	466	$	806
Restricted cash		50		50
Total cash and restricted cash as shown in the statements of cash flows	$	516	$	856

Recently Adopted Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Notes Payable	3 Months Ended
Notes Payable	Mar. 31, 2021
Notes Payable
Notes Payable	3. Notes Payable On May 4, 2020, the Company obtained a loan (Loan) from the Bank of America (Lender) in the aggregate amount of $0.4 million, pursuant to the Paycheck Protection Plan (PPP), established as part of the CARES Act. The Loan is evidenced by a promissory note dated May 4, 2020 issued by the Company and will accrue interest at a fixed interest rate of 1% per annum from the funding date of May 4, 2020. Payments of principal and interest have been deferred since the funding under the original terms of the promissory note. However, the Loan and accrued interest may be forgivable at the conclusion of this period. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The terms of the promissory note, including eligibility and forgiveness, may be subject to additional requirements adopted by the SBA. Any unforgiven portion of the PPP loan, including principal and interest, will mature on May 4, 2022 and will be required to be payable monthly. The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The Company has accounted for the loan under FASB ASC 470, Debt. Repayment amounts due within one year have been recorded as current liabilities, and the remaining amounts due in more than one year as long-term liabilities. On December 18, 2020, the Company submitted the loan forgiveness application for the entire borrowings of $0.4 million to the Lender and was notified on January 7, 2021 that the application was submitted to the Small Business Administration (SBA) for review. The SBA had up to 90 days from the date of submittal to make a final decision on loan forgiveness. The Company has yet to be notified of the SBA’s forgiveness decision. If the Company is successful in receiving forgiveness for any portion of the loan used for qualifying expenses, those amounts will be recorded as a gain upon extinguishment.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Capital Stock

3 Months Ended

Mar. 31, 2021

Capital Stock

Capital Stock

4. Capital Stock


Risk-free interest rate		0.88	%
Expected volatility		106.7	%
Expected term		2	months
Expected dividend yield		—
Exercise price	$	3.70
Market value of common stock	$	3.11

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2021

Fair Value Measurements

Fair Value Measurements

5. Fair Value Measurements


	Warrant Liability
	(In thousands)
Balance at December 31, 2020	$	17
Change in fair value upon re-measurement		(3)
Balance at March 31, 2021	$	14


	March 31,			December 31,
	2021			2020
Risk-free interest rate		0.16	%		0.12	%
Expected volatility		140.08	%		137.89	%
Expected term (in years)		0.9			1.1
Expected dividend yield		—			—
Exercise price	$	8.00		$	8.00
Market value of common stock	$	1.34		$	1.25
Warrants to purchase shares of common stock		92,212			92,212

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

3 Months Ended

Mar. 31, 2021

Share-Based Compensation

Share-Based Compensation

6. Share-Based Compensation

Biostage Amended and Restated Equity Incentive Plan

The Company has granted options to purchase common stock under the Plan. Stock option activity during the three months ended March 31, 2021 was as follows:


	Stock Options
		Weighted –
		average
	Amount	exercise price
Outstanding at December 31, 2020	1,599,720	$	6.33
Granted	16,413		1.80
Canceled	—		—
Outstanding at March 31, 2021	1,616,134	$	6.31


Risk-free interest rate	0.47	%
Expected volatility	123.20	%
Expected term	5.3	years
Expected dividend yield	n/a

The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations:


	Three Months Ended March 31,
	2021		2020
	(In thousands)
Research and development	$	80	$	92
General and administrative		50		496
Total share-based compensation	$	130	$	588

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2021
Commitments and Contingencies
Commitments and Contingencies	7. Commitments and Contingencies On April 14, 2017, representatives for the estate of a deceased individual filed a civil lawsuit in the Suffolk Superior Court, in Boston, Massachusetts, against the Company and Harvard Bioscience. The complaint alleges that the decedent’s injury and death were caused by two tracheal implants that incorporated synthetic trachea scaffolds and a biologic component combined by the implanting surgeon with a bioreactor, and surgically implanted in the decedent in two surgeries performed in 2012 and 2013. The civil complaint seeks a non-specific sum of money to compensate the plaintiffs. This civil lawsuit relates to the Company’s first-generation trachea scaffold technology for which the Company discontinued development in 2014, and not to the Company’s current Cellspan technology nor to its lead development product candidate, the Cellspan Esophageal Implant. The Company intends to vigorously defend this case. While the Company believes that such claim lacks merit, the Company is unable to predict the ultimate outcome of such litigation. In accordance with a separation and distribution agreement between Harvard Bioscience and the Company relating to the spin-off, the Company would be required to indemnify Harvard Bioscience against losses that Harvard Bioscience may suffer as a result of this litigation. The Company has been informed by its insurance provider that the case has been accepted as an insurable claim under the Company’s product liability insurance policy. The Company does not believe a loss is probable at this time and therefore has not accrued any amounts for this contingent liability. From time to time, the Company may be involved in various claims and legal proceedings arising in the ordinary course of business. Other than the above matter, there are no such matters pending that the Company expects to be material in relation to its business, financial condition, results of operations, or cash flows.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2021

Leases

Leases

8. Leases

The Company leases laboratory and office space and certain equipment with remaining terms ranging approximately from 1 year to 3.5 years.

All of the Company’s leases qualify as operating leases. The following table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets:


		For the Quarter ended March 31
(In thousands)	Balance Sheet Classification	2021		2020
Assets:
Operating lease assets	Right-of-use asset	$	156	$	166

Liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	110	$	105
Non-current operating lease liabilities	Operating lease liabilities, net of current portion	$	46	$	61
Total operating lease liabilities		$	156	$	166

Cash paid included in the computation of the right of use asset and lease liability during the three months ended March 31, 2021 and 2020 amounted to approximately $30,000, respectively.

The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:


	As of March 31,
	2021		2020
Weighted average remaining lease term (in years)	1.72		2.20
Weighted average discount rate	10.24	%	13.13	%

The Company recorded lease expense in the following expense categories of its consolidated statements of operations:


			For the Three Months
			Ended March 31,
(In thousands)	Statement of Operations Classification		2021		2020
Operating lease expense	Research and development	$	19	$	19
	Selling, general and administrative		11		11
		$	30	$	30

The minimum lease payments for the next five years are expected to be as follows:


	As Of
	March 31,
(In thousands)	2021
2020	$	91
2021		62
2022		12
2023		7
2024		—
Total lease payments	$	172
Less: imputed interest		16
Present value of operating lease liabilities	$	156

XML 26 R15.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2021

Net Loss Per Share

Net Loss Per Share

9. Net Loss Per Share

Basic and diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding.


	Three Months Ended March 31,
	2021	2020

Warrants to purchase common stock	1,893,201	2,610,078
Options to purchase common stock	1,616,134	1,607,570
Common stock awards	—	20,000
Total	3,509,335	4,237,648

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2021
Income Taxes
Income Taxes	10. Income Taxes The Company did not record a federal or state income tax provision or benefit for the three months ended March 31, 2021 and 2020, respectively, due to the expected loss before income taxes to be incurred for the years ended December 31, 2021 and 2020, as well as the Company’s continued maintenance of a full valuation allowance against its net deferred tax assets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2021
Subsequent Events
Subsequent Events	11. Subsequent Events Equity Transactions In May 2021, the Company received aggregate gross and net proceeds of approximately $0.3 million from a group of existing investors.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Policies)

3 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

SBIR Award

Grant income is recognized when qualified research and development costs are incurred and recorded in other income (expense), net in the consolidated statements of operations. When evaluating grant revenue from the SBIR grant, the Company considered accounting requirements under the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606, Revenue From Contracts With Customers. The Company concluded that ASC 606 did not apply as there is no exchange of goods or services or an exchange of intellectual property between the parties; therefore, the Company presents grant income in other income.

The Company did not recognize any grant income during the three months ended March 31, 2020.

Restricted Cash

A reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statements of cash flows is as follows:


	March 31,		December 31,
	2021		2020
	(In thousands)
Cash	$	466	$	806
Restricted cash		50		50
Total cash and restricted cash as shown in the statements of cash flows	$	516	$	856

Recently Adopted Accounting Pronouncements

XML 30 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Tables)

3 Months Ended

Mar. 31, 2021

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements

Schedule of reconciliation of the cash and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the consolidated statements of cash flows


	March 31,		December 31,
	2021		2020
	(In thousands)
Cash	$	466	$	806
Restricted cash		50		50
Total cash and restricted cash as shown in the statements of cash flows	$	516	$	856

XML 31 R20.htm IDEA: XBRL DOCUMENT

Capital Stock (Tables)

3 Months Ended

Mar. 31, 2021

Capital Stock

Schedule of Classification of warrants to equity


Risk-free interest rate		0.88	%
Expected volatility		106.7	%
Expected term		2	months
Expected dividend yield		—
Exercise price	$	3.70
Market value of common stock	$	3.11

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2021

Fair Value Measurements

Schedule of reconciliation company's liabilities at fair value on recurring basis


	Warrant Liability
	(In thousands)
Balance at December 31, 2020	$	17
Change in fair value upon re-measurement		(3)
Balance at March 31, 2021	$	14

Schedule of weighted average assumptions


	March 31,			December 31,
	2021			2020
Risk-free interest rate		0.16	%		0.12	%
Expected volatility		140.08	%		137.89	%
Expected term (in years)		0.9			1.1
Expected dividend yield		—			—
Exercise price	$	8.00		$	8.00
Market value of common stock	$	1.34		$	1.25
Warrants to purchase shares of common stock		92,212			92,212

XML 33 R22.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Share-Based Compensation

Schedule of Stock option and restricted stock unit activity

The Company has granted options to purchase common stock under the Plan. Stock option activity during the three months ended March 31, 2021 was as follows:


	Stock Options
		Weighted –
		average
	Amount	exercise price
Outstanding at December 31, 2020	1,599,720	$	6.33
Granted	16,413		1.80
Canceled	—		—
Outstanding at March 31, 2021	1,616,134	$	6.31

Schedule of weighted average assumptions


Risk-free interest rate	0.47	%
Expected volatility	123.20	%
Expected term	5.3	years
Expected dividend yield	n/a

Schedule of share-based compensation expense

The Company recorded share-based compensation expense in the following expense categories of its consolidated statements of operations:


	Three Months Ended March 31,
	2021		2020
	(In thousands)
Research and development	$	80	$	92
General and administrative		50		496
Total share-based compensation	$	130	$	588

XML 34 R23.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Mar. 31, 2021

Leases

Summary of presentation of operating leases in consolidated balance sheets

The following table summarizes the presentation of the Company’s operating leases in its consolidated balance sheets:


		For the Quarter ended March 31
(In thousands)	Balance Sheet Classification	2021		2020
Assets:
Operating lease assets	Right-of-use asset	$	156	$	166

Liabilities:
Current operating lease liabilities	Current portion of operating lease liabilities	$	110	$	105
Non-current operating lease liabilities	Operating lease liabilities, net of current portion	$	46	$	61
Total operating lease liabilities		$	156	$	166

Schedule of Weighted average discount rate and lease term

The weighted average remaining lease term and weighted average discount rate of the Company’s operating leases are as follows:


	As of March 31,
	2021		2020
Weighted average remaining lease term (in years)	1.72		2.20
Weighted average discount rate	10.24	%	13.13	%

Summary of lease expense categories in consolidated statements of operations

The Company recorded lease expense in the following expense categories of its consolidated statements of operations:


			For the Three Months
			Ended March 31,
(In thousands)	Statement of Operations Classification		2021		2020
Operating lease expense	Research and development	$	19	$	19
	Selling, general and administrative		11		11
		$	30	$	30

Summary of minimum lease payments for the next five years and thereafter

The minimum lease payments for the next five years are expected to be as follows:


	As Of
	March 31,
(In thousands)	2021
2020	$	91
2021		62
2022		12
2023		7
2024		—
Total lease payments	$	172
Less: imputed interest		16
Present value of operating lease liabilities	$	156

XML 35 R24.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Net Loss Per Share

Schedule of antidilutive securities excluded from computation of earnings per share


	Three Months Ended March 31,
	2021	2020

Warrants to purchase common stock	1,893,201	2,610,078
Options to purchase common stock	1,616,134	1,607,570
Common stock awards	—	20,000
Total	3,509,335	4,237,648

XML 36 R25.htm IDEA: XBRL DOCUMENT

Overview and Basis of Presentation (Details) - USD ($) $ in Thousands	1 Months Ended
	May 31, 2021	Oct. 31, 2013	Mar. 31, 2021	Dec. 31, 2020
Overview And Basis Of Presentation [Line Items]
Retained Earnings (Accumulated Deficit)			$ (69,834)	$ (68,960)
Cash			$ 466
Harvard Bioscience Plan [Member]
Overview And Basis Of Presentation [Line Items]
Proceeds from Contributions from Parent		$ 15,000
Subsequent Event [Member] \| Existing Investors
Overview And Basis Of Presentation [Line Items]
Cash proceeds received	$ 300

XML 37 R26.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended
	Oct. 26, 2018	Mar. 28, 2018	Mar. 31, 2021	Dec. 31, 2020	Aug. 03, 2020
Basic And Diluted Earnings Per Share [Line Items]
Recognized grants receivable	$ 1,400,000
Restricted Cash			$ 50,000	$ 50,000
Maximum Research And Development Expenses Reimbursement		$ 200,000
Grants Receivable	1,800,000
Phase Two [Member]
Basic And Diluted Earnings Per Share [Line Items]
Grants Receivable in fiscal year	$ 1,100,000				$ 500,000
Grant Income Recognized			$ 100,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Cash and restricted cash (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements
Cash	$ 466
Restricted cash	50	$ 50
Total cash and restricted cash as shown in the consolidated statements of cash flows	$ 516		$ 856	$ 963

XML 39 R28.htm IDEA: XBRL DOCUMENT

Notes Payable (Details) - Paycheck Protection Program loan [Member] - USD ($) $ in Millions	Dec. 18, 2020	May 04, 2020
Debt Instrument [Line Items]
Proceeds from Issuance of Debt	$ 0.4	$ 0.4
Fixed interest rate		1.00%

XML 40 R29.htm IDEA: XBRL DOCUMENT

Capital Stock (Details)	3 Months Ended
Capital Stock (Details)	Mar. 31, 2020 $ / shares
Capital Stock
Risk-free interest rate	0.88%
Expected volatility	106.70%
Expected term (in months)	2 months
Expected dividend yield	0.00%
Exercise price	$ 3.70
Market value of common stock	$ 3.11

XML 41 R30.htm IDEA: XBRL DOCUMENT

Capital Stock - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	92,212		92,212
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8.00		$ 8.00
Proceeds from Issuance of Private Placement	$ 0	$ 559,000
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		100,000
Gross and net proceeds from issuance		$ 600,000
Restricted Stock [Member]
Stock Issued During Period, Shares, New Issues		11,950
Common Stock [Member]
Warrants and Rights Outstanding		$ 500,000
Warrant One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		151,027
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 3.70
Share Price		$ 3.70
Stock Issued During Period, Value, New Issues		$ 151,027
Warrant Two [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.00
Proceeds from Warrant Exercises		$ 400,000
Stock Issued During Period, Shares, New Issues		214,000
Shares Issued As A Result Of Exercise Of Warrants		214,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Reconciliation of company liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Fair Value Measurements
Beginning Balance	$ 17
Change in fair value upon re-measurement	(3)
Ending Balance	$ 14

XML 43 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Liabilities:
Liabilities classified	$ 14	$ 17
Level 2 [Member]
Assets:
Assets classified	0	0
Liabilities:
Liabilities classified	$ 0	$ 0

XML 44 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Weighted average assumptions (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Exercise Price	$ 8.00	$ 8.00
Market value of common stock	$ 1.34	$ 1.25
Warrants to purchase shares of common stock	92,212	92,212
Measurement Input, Risk Free Interest Rate [Member]
Risk-free interest rate	0.16%	0.12%
Measurement Input, Price Volatility [Member]
Expected volatility	140.08	137.89
Measurement Input, Expected Term [Member]
Expected term (in years)	10 months 24 days	1 year 1 month 6 days
Measurement Input, Expected Dividend Rate [Member]
Expected dividend yield	0.00%	0.00%

XML 45 R34.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Stock option and restricted stock unit activity (Details) - Biostage2013 Equity Incentive Plan [Member] - Stock Options [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Amount, Outstanding \| shares	1,599,720
Amount, Granted \| shares	16,413
Amount, Outstanding \| shares	1,616,134
Weighted-average exercise price, Outstanding \| $ / shares	$ 6.33
Weighted-average exercise price, Granted \| $ / shares	1.80
Weighted-average exercise price, Outstanding \| $ / shares	$ 6.31

XML 46 R35.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Weighted average assumptions (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		0.88%
Expected volatility		106.70%
Expected term (in years)		2 months
Expected dividend yield		0.00%
Biostage2013 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.47%
Expected volatility	123.20%
Expected term (in years)	5 years 3 months 18 days

XML 47 R36.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Share-based compensation expenses (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 70,000	$ 130	$ 588
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation		80	92
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation		$ 50	$ 496

XML 48 R37.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Details) - USD ($)		1 Months Ended			3 Months Ended
	Mar. 27, 2020	Jun. 30, 2020	Mar. 31, 2020	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense				$ 70,000,000	$ 130,000	$ 588,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense				4,000,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					243,532
Share Based Compensation Arrangement By Share Based Payment Award Unrecognized Compensation Costs					$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					338,663
Allocated Share-based Compensation Expense					$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number					338,663
Number of options outstanding at September 30, 2020					338,663
Common Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	9,795		35,000
Allocated Share-based Compensation Expense			$ 74,800,000
Number of awards issued	9,795		35,000
Number of common shares whose milestone were achieved	15,000
Number of fully vested shares withheld	5,205
Expense to be recognized upon the achievement of certain milestones			$ 65,200,000			$ 65,200,000
Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense				153,000,000
Stock options issued				$ 80,000,000
Number of options to purchase common stock modified				236,970
Chief Financial Officer [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards whose vesting was accelerated				3,300
Biostage Amended and Restated Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		5,098,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized					$ 300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value					$ 0
Share Price					$ 1.34
Shares available for issuance					3,461,091

XML 49 R38.htm IDEA: XBRL DOCUMENT

Leases (Details)	3 Months Ended
Leases (Details)	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Renewal term	1 year
Termination option	false
Notice period for termination	180 days
Minimum [Member]
Lessee, Lease, Description [Line Items]
Remaining term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Remaining term	3 years 6 months

XML 50 R39.htm IDEA: XBRL DOCUMENT

Leases - Operating leases in consolidated balance sheets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
Leases
Operating lease assets	$ 156	$ 182	$ 166
Right-of-use asset	Operating lease assets
Current portion of operating lease liabilities	$ 110	107	105
Current portion of operating lease liabilities	Current portion of operating lease liabilities
Non-current Operating lease liabilities	$ 46	$ 75	61
Operating lease liabilities, net of current portion	Non-current Operating lease liabilities
Present value of operating lease liabilities	$ 156		$ 166

XML 51 R40.htm IDEA: XBRL DOCUMENT

Leases - Weighted average discount rate and lease term (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases
Cash paid included in the computation of the right of use asset and lease liability	$ 30,000
Weighted average remaining lease term (in years)	0 years	2 years 2 months 12 days
Weighted average discount rate	0.00%	13.13%

XML 52 R41.htm IDEA: XBRL DOCUMENT

Leases - Operating lease expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Research and development	$ 473	$ 643
Selling, general and administrative	522	1,253
Assets Leased To Other [Member]
Research and development	19	19
Selling, general and administrative	11	11
Operating lease expense	$ 30	$ 30

XML 53 R42.htm IDEA: XBRL DOCUMENT

Leases - Minimum lease payments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Minimum lease payments for the next five years and thereafter
2020	$ 91
2021	62
2022	12
2023	7
Total lease payments	172
Less: imputed interest	16
Present value of operating lease liabilities	$ 156	$ 166

XML 54 R43.htm IDEA: XBRL DOCUMENT

Net loss Per Share - Anti-dilutive shares (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,509,335	4,237,648
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,893,201	2,610,078
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,616,134	1,607,570
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	20,000

XML 55 R44.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	May 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 8.00	$ 8.00
Subsequent Event [Member] \| Existing Investors
Subsequent Event [Line Items]
Gross and net proceeds from issuance	$ 0.3

EXCEL 56 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 57 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 58 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 84 263 1 false 32 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.biostage.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.biostage.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.biostage.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.biostage.com/role/StatementConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.biostage.com/role/StatementConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.biostage.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Overview and Basis of Presentation Sheet http://www.biostage.com/role/DisclosureOverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 7 false false R8.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.biostage.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 10301 - Disclosure - Notes Payable Notes http://www.biostage.com/role/DisclosureNotesPayable Notes Payable Notes 9 false false R10.htm 10401 - Disclosure - Capital Stock Sheet http://www.biostage.com/role/DisclosureCapitalStock Capital Stock Notes 10 false false R11.htm 10501 - Disclosure - Fair Value Measurements Sheet http://www.biostage.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 10601 - Disclosure - Share-Based Compensation Sheet http://www.biostage.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 12 false false R13.htm 10701 - Disclosure - Commitments and Contingencies Sheet http://www.biostage.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 10801 - Disclosure - Leases Sheet http://www.biostage.com/role/DisclosureLeases Leases Notes 14 false false R15.htm 10901 - Disclosure - Net Loss Per Share Sheet http://www.biostage.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 11001 - Disclosure - Income Taxes Sheet http://www.biostage.com/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 11101 - Disclosure - Subsequent Events Sheet http://www.biostage.com/role/DisclosureSubsequentEvents Subsequent Events Notes 17 false false R18.htm 20202 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Policies) Sheet http://www.biostage.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentlyIssuedAccountingPronouncementsPolicies Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Policies) Policies http://www.biostage.com/role/DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm 30203 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Tables) Sheet http://www.biostage.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentlyIssuedAccountingPronouncementsTables Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements (Tables) Tables 19 false false R20.htm 30403 - Disclosure - Capital Stock (Tables) Sheet http://www.biostage.com/role/DisclosureCapitalStockTables Capital Stock (Tables) Tables http://www.biostage.com/role/DisclosureCapitalStock 20 false false R21.htm 30503 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.biostage.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.biostage.com/role/DisclosureFairValueMeasurements 21 false false R22.htm 30603 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.biostage.com/role/DisclosureShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.biostage.com/role/DisclosureShareBasedCompensation 22 false false R23.htm 30803 - Disclosure - Leases (Tables) Sheet http://www.biostage.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.biostage.com/role/DisclosureLeases 23 false false R24.htm 30903 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.biostage.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.biostage.com/role/DisclosureNetLossPerShare 24 false false R25.htm 40101 - Disclosure - Overview and Basis of Presentation (Details) Sheet http://www.biostage.com/role/DisclosureOverviewAndBasisOfPresentationDetails Overview and Basis of Presentation (Details) Details http://www.biostage.com/role/DisclosureOverviewAndBasisOfPresentation 25 false false R26.htm 40201 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Additional Information (Details) Sheet http://www.biostage.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentlyIssuedAccountingPronouncementsAdditionalInformationDetails Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Additional Information (Details) Details 26 false false R27.htm 40202 - Disclosure - Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Cash and restricted cash (Details) Sheet http://www.biostage.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentlyIssuedAccountingPronouncementsCashAndRestrictedCashDetails Summary of Significant Accounting Policies and Recently Issued Accounting Pronouncements - Cash and restricted cash (Details) Details 27 false false R28.htm 40301 - Disclosure - Notes Payable (Details) Notes http://www.biostage.com/role/DisclosureNotesPayableDetails Notes Payable (Details) Details http://www.biostage.com/role/DisclosureNotesPayable 28 false false R29.htm 40401 - Disclosure - Capital Stock (Details) Sheet http://www.biostage.com/role/DisclosureCapitalStockDetails Capital Stock (Details) Details http://www.biostage.com/role/DisclosureCapitalStockTables 29 false false R30.htm 40402 - Disclosure - Capital Stock - Additional Information (Details) Sheet http://www.biostage.com/role/DisclosureCapitalStockAdditionalInformationDetails Capital Stock - Additional Information (Details) Details 30 false false R31.htm 40501 - Disclosure - Fair Value Measurements - Reconciliation of company liabilities (Details) Sheet http://www.biostage.com/role/DisclosureFairValueMeasurementsReconciliationOfCompanyLiabilitiesDetails Fair Value Measurements - Reconciliation of company liabilities (Details) Details 31 false false R32.htm 40502 - Disclosure - Fair Value Measurements (Details) Sheet http://www.biostage.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://www.biostage.com/role/DisclosureFairValueMeasurementsTables 32 false false R33.htm 40503 - Disclosure - Fair Value Measurements - Weighted average assumptions (Details) Sheet http://www.biostage.com/role/DisclosureFairValueMeasurementsWeightedAverageAssumptionsDetails Fair Value Measurements - Weighted average assumptions (Details) Details 33 false false R34.htm 40601 - Disclosure - Share-Based Compensation - Stock option and restricted stock unit activity (Details) Sheet http://www.biostage.com/role/DisclosureShareBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails Share-Based Compensation - Stock option and restricted stock unit activity (Details) Details 34 false false R35.htm 40602 - Disclosure - Share-Based Compensation - Weighted average assumptions (Details) Sheet http://www.biostage.com/role/DisclosureShareBasedCompensationWeightedAverageAssumptionsDetails Share-Based Compensation - Weighted average assumptions (Details) Details 35 false false R36.htm 40603 - Disclosure - Share-Based Compensation - Share-based compensation expenses (Details) Sheet http://www.biostage.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails Share-Based Compensation - Share-based compensation expenses (Details) Details 36 false false R37.htm 40604 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.biostage.com/role/DisclosureShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 37 false false R38.htm 40801 - Disclosure - Leases (Details) Sheet http://www.biostage.com/role/DisclosureLeasesDetails Leases (Details) Details http://www.biostage.com/role/DisclosureLeasesTables 38 false false R39.htm 40802 - Disclosure - Leases - Operating leases in consolidated balance sheets (Details) Sheet http://www.biostage.com/role/DisclosureLeasesOperatingLeasesInConsolidatedBalanceSheetsDetails Leases - Operating leases in consolidated balance sheets (Details) Details 39 false false R40.htm 40803 - Disclosure - Leases - Weighted average discount rate and lease term (Details) Sheet http://www.biostage.com/role/DisclosureLeasesWeightedAverageDiscountRateAndLeaseTermDetails Leases - Weighted average discount rate and lease term (Details) Details 40 false false R41.htm 40804 - Disclosure - Leases - Operating lease expense (Details) Sheet http://www.biostage.com/role/DisclosureLeasesOperatingLeaseExpenseDetails Leases - Operating lease expense (Details) Details 41 false false R42.htm 40805 - Disclosure - Leases - Minimum lease payments (Details) Sheet http://www.biostage.com/role/DisclosureLeasesMinimumLeasePaymentsDetails Leases - Minimum lease payments (Details) Details 42 false false R43.htm 40901 - Disclosure - Net loss Per Share - Anti-dilutive shares (Details) Sheet http://www.biostage.com/role/DisclosureNetLossPerShareAntiDilutiveSharesDetails Net loss Per Share - Anti-dilutive shares (Details) Details 43 false false R44.htm 41101 - Disclosure - Subsequent Events (Details) Sheet http://www.biostage.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.biostage.com/role/DisclosureSubsequentEvents 44 false false All Reports Book All Reports bstg-20210331.xml bstg-20210331.xsd bstg-20210331_cal.xml bstg-20210331_def.xml bstg-20210331_lab.xml bstg-20210331_pre.xml http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 62 0001104659-21-071224-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-071224-xbrl.zip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end